1
|
Rekima A, van den Elsen L, Isnard C, Smyth DJ, Lynn MA, Yee T, Stevens NE, Machado S, Divakara N, Bhasin M, Tjiam MC, Rowel C, Servant F, Burcelin R, Locksley R, Maizels R, Lynn DJ, Egwang T, Verhasselt V. Colostrum is required for the postnatal ontogeny of small intestine innate lymphoid type 2 cells and successful anti-helminth defences. Allergy 2024. [PMID: 38348877 DOI: 10.1111/all.16054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 01/19/2024] [Accepted: 02/05/2024] [Indexed: 02/17/2024]
Affiliation(s)
- Akila Rekima
- Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia
- Telethon Kids Institute, Nedlands, Western Australia, Australia
| | - Lieke van den Elsen
- Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia
- Telethon Kids Institute, Nedlands, Western Australia, Australia
| | | | - Danielle J Smyth
- Wellcome Centre for Integrative Parasitology, University of Glasgow, Glasgow, UK
| | - Miriam A Lynn
- The South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia
| | - Tee Yee
- The South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Natalie E Stevens
- The South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia
| | - Savannah Machado
- Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia
- Telethon Kids Institute, Nedlands, Western Australia, Australia
| | - Nivedithaa Divakara
- Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia
- Telethon Kids Institute, Nedlands, Western Australia, Australia
| | - Maheshwar Bhasin
- Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia
- Telethon Kids Institute, Nedlands, Western Australia, Australia
| | - M Christian Tjiam
- Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia
- Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia
| | - Candia Rowel
- Vector Control Division, Ministry of Health, Kampala, Uganda
| | | | - Remy Burcelin
- Vaiomer SAS, Toulouse-Labège, France
- I2MC, INSERM 1297, Toulouse, France
| | - Richard Locksley
- Department of Medicine, University of California San Francisco, San Francisco, California, USA
| | - Rick Maizels
- Wellcome Centre for Integrative Parasitology, University of Glasgow, Glasgow, UK
| | - David J Lynn
- The South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia
| | | | - Valérie Verhasselt
- Larsson-Rosenquist Centre for Immunology and Breastfeeding, School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia
- Telethon Kids Institute, Nedlands, Western Australia, Australia
| |
Collapse
|
2
|
Lê S, Laurencin-Dalicieux S, Minty M, Assoulant-Anduze J, Vinel A, Yanat N, Loubieres P, Azalbert V, Diemer S, Burcelin R, Canceill T, Thomas C, Blasco-Baque V. Obesity Is Associated with the Severity of Periodontal Inflammation Due to a Specific Signature of Subgingival Microbiota. Int J Mol Sci 2023; 24:15123. [PMID: 37894804 PMCID: PMC10606428 DOI: 10.3390/ijms242015123] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/05/2023] [Accepted: 10/05/2023] [Indexed: 10/29/2023] Open
Abstract
The aim of this study was to analyze the link between periodontal microbiota and obesity in humans. We conducted a cohort study including 45 subjects with periodontitis divided into two groups: normo-weighted subjects with a body mass index (BMI) between 20 and 25 kg/m2 (n = 34) and obese subjects with a BMI > 30 kg/m2 (n = 11). Our results showed that obesity was associated with significantly more severe gingival inflammation according to Periodontal Inflamed Surface Area (PISA index). Periodontal microbiota taxonomic analysis showed that the obese (OB) subjects with periodontitis were characterized by a specific signature of subgingival microbiota with an increase in Gram-positive bacteria in periodontal pockets, associated with a decrease in microbiota diversity compared to that of normo-weighted subjects with periodontitis. Finally, periodontal treatment response was less effective in OB subjects with persisting periodontal inflammation, reflecting a still unstable periodontal condition and a risk of recurrence. To our knowledge, this study is the first exploring both salivary and subgingival microbiota of OB subjects. Considering that OB subjects are at higher periodontal risk, this could lead to more personalized preventive or therapeutic strategies for obese patients regarding periodontitis through the specific management of oral microbiota of obese patients.
Collapse
Affiliation(s)
- Sylvie Lê
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Sara Laurencin-Dalicieux
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- INSERM U1295, CERPOP, Epidémiologie et Analyse en Santé Publique, Risques, Maladies Chroniques et Handicaps, 37 Allées Jules Guesdes, 31000 Toulouse, France
| | - Matthieu Minty
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Justine Assoulant-Anduze
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Alexia Vinel
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- UMR 1297 Inserm, Team ESTER, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France
| | - Noor Yanat
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
| | - Pascale Loubieres
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Vincent Azalbert
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Swann Diemer
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Remy Burcelin
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Thibault Canceill
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Charlotte Thomas
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| | - Vincent Blasco-Baque
- Département d’Odontologie, Faculté de Santé, Université Paul Sabatier Toulouse III, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (S.L.); (S.L.-D.); (M.M.); (A.V.); (N.Y.); (P.L.)
- Service d’Odontologie Toulouse Rangueil, CHU Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- UMR1297 Inserm, Team InCOMM/Intestine ClinicOmics Metabolism & Microbiota, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier, 1 Avenue Jean Poulhes, 31432 Toulouse, France; (J.A.-A.); (V.A.); (S.D.); (R.B.)
| |
Collapse
|
3
|
Schoeler M, Ellero-Simatos S, Birkner T, Mayneris-Perxachs J, Olsson L, Brolin H, Loeber U, Kraft JD, Polizzi A, Martí-Navas M, Puig J, Moschetta A, Montagner A, Gourdy P, Heymes C, Guillou H, Tremaroli V, Fernández-Real JM, Forslund SK, Burcelin R, Caesar R. The interplay between dietary fatty acids and gut microbiota influences host metabolism and hepatic steatosis. Nat Commun 2023; 14:5329. [PMID: 37658064 PMCID: PMC10474162 DOI: 10.1038/s41467-023-41074-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 08/21/2023] [Indexed: 09/03/2023] Open
Abstract
Dietary lipids can affect metabolic health through gut microbiota-mediated mechanisms, but the influence of lipid-microbiota interaction on liver steatosis is largely unknown. We investigate the impact of dietary lipids on human gut microbiota composition and the effects of microbiota-lipid interactions on steatosis in male mice. In humans, low intake of saturated fatty acids (SFA) is associated with increased microbial diversity independent of fiber intake. In mice, poorly absorbed dietary long-chain SFA, particularly stearic acid, induce a shift in bile acid profile and improved metabolism and steatosis. These benefits are dependent on the gut microbiota, as they are transmitted by microbial transfer. Diets enriched in polyunsaturated fatty acids are protective against steatosis but have minor influence on the microbiota. In summary, we find that diets enriched in poorly absorbed long-chain SFA modulate gut microbiota profiles independent of fiber intake, and this interaction is relevant to improve metabolism and decrease liver steatosis.
Collapse
Affiliation(s)
- Marc Schoeler
- The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Sandrine Ellero-Simatos
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Till Birkner
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125, Berlin, Germany
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany
| | - Jordi Mayneris-Perxachs
- Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, Girona, Spain
- Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IdibGi), Girona, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
| | - Lisa Olsson
- The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Harald Brolin
- The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Ulrike Loeber
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125, Berlin, Germany
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany
- Experimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
| | - Jamie D Kraft
- The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - Arnaud Polizzi
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Marian Martí-Navas
- Department of Radiology, Biomedical Research Institute Imaging Research Unit, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital of Girona, Avinguda de França, s/n, 17007, Girona, Catalonia, Spain
| | - Josep Puig
- Department of Radiology, Biomedical Research Institute Imaging Research Unit, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital of Girona, Avinguda de França, s/n, 17007, Girona, Catalonia, Spain
| | - Antonio Moschetta
- Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy
- Medicina e Chirurgia d'Accettazione E d'Urgenza, Azienda Ospedaliero-Universitaria Policlinico di Bari, 70124, Bari, Italy
- Medicina Sub-Intensiva, Presidio Maxi-Emergenze Fiera del Levante, Azienda Ospedaliero-Universitaria Policlinico di Bari, 70124, Bari, Italy
| | - Alexandra Montagner
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR 1297, Université Paul Sabatier, Université de Toulouse, F-31432, Toulouse, France
| | - Pierre Gourdy
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR 1297, Université Paul Sabatier, Université de Toulouse, F-31432, Toulouse, France
- Endocrinology-Diabetology-Nutrition Department, Toulouse University Hospital, Toulouse, France
| | - Christophe Heymes
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR 1297, Université Paul Sabatier, Université de Toulouse, F-31432, Toulouse, France
| | - Hervé Guillou
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Valentina Tremaroli
- The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden
| | - José Manuel Fernández-Real
- Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta University Hospital, Girona, Spain
- Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IdibGi), Girona, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
- Department of Medical Sciences, Faculty of Medicine, Girona University, Girona, Spain
| | - Sofia K Forslund
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125, Berlin, Germany
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany
- Experimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany
- Structural and Computational Biology Unit, European Molecular Biology Laboratory, 69117, Heidelberg, Germany
| | - Remy Burcelin
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR 1297, Université Paul Sabatier, Université de Toulouse, F-31432, Toulouse, France
| | - Robert Caesar
- The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
| |
Collapse
|
4
|
Effenberger M, Waschina S, Bronowski C, Sturm G, Tassiello O, Sommer F, Zollner A, Watschinger C, Grabherr F, Gstir R, Grander C, Enrich B, Bale R, Putzer D, Djanani A, Moschen AR, Zoller H, Rupp J, Schreiber S, Burcelin R, Lass-Flörl C, Trajanoski Z, Oberhuber G, Rosenstiel P, Adolph TE, Aden K, Tilg H. A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma. Hepatol Commun 2023; 7:e00182. [PMID: 37314752 DOI: 10.1097/hc9.0000000000000182] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Accepted: 04/18/2023] [Indexed: 06/15/2023] Open
Abstract
BACKGROUND HCC is the leading cause of cancer in chronic liver disease. A growing body of experimental mouse models supports the notion that gut-resident and liver-resident microbes control hepatic immune responses and, thereby, crucially contribute to liver tumorigenesis. However, a comprehensive characterization of the intestinal microbiome in fueling the transition from chronic liver disease to HCC in humans is currently missing. METHODS Here, we profiled the fecal, blood, and liver tissue microbiome of patients with HCC by 16S rRNA sequencing and compared profiles to nonmalignant cirrhotic and noncirrhotic NAFLD patients. RESULTS We report a distinct bacterial profile, defined from 16S rRNA gene sequences, with reduced α-and β-diversity in the feces of patients with HCC and cirrhosis compared to NAFLD. Patients with HCC and cirrhosis exhibited an increased proportion of fecal bacterial gene signatures in the blood and liver compared to NAFLD. Differential analysis of the relative abundance of bacterial genera identified an increased abundance of Ruminococcaceae and Bacteroidaceae in blood and liver tissue from both HCC and cirrhosis patients compared to NAFLD. Fecal samples from cirrhosis and HCC patients both showed a reduced abundance for several taxa, including short-chain fatty acid-producing genera, such as Blautia and Agathobacter. Using paired 16S rRNA and transcriptome sequencing, we identified a direct association between gut bacterial genus abundance and host transcriptome response within the liver tissue. CONCLUSIONS Our study indicates perturbations of the intestinal and liver-resident microbiome as a critical determinant of patients with cirrhosis and HCC.
Collapse
Affiliation(s)
- Maria Effenberger
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Silvio Waschina
- Institute for Human Nutrition and Food Science, Division of Nutriinformatics, Christian-Albrechts-University of Kiel, Kiel, Germany
| | - Christina Bronowski
- Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
| | - Gregor Sturm
- Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria
| | - Oronzo Tassiello
- Institute for Human Nutrition and Food Science, Division of Nutriinformatics, Christian-Albrechts-University of Kiel, Kiel, Germany
| | - Felix Sommer
- Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
| | - Andreas Zollner
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Christina Watschinger
- Department of Internal Medicine I, Gastroenterology, Nephrology, Metabolism & Endocrinology, Johannes Kepler University, Linz, Austria
| | - Felix Grabherr
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Ronald Gstir
- Institute of Hygiene and Medical Microbiology, ECMM, Medical University of Innsbruck, Innsbruck, Austria
| | - Christoph Grander
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Barbara Enrich
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Reto Bale
- Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
| | - Daniel Putzer
- Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
| | - Angela Djanani
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Alexander R Moschen
- Department of Internal Medicine I, Gastroenterology, Nephrology, Metabolism & Endocrinology, Johannes Kepler University, Linz, Austria
- Christian Doppler Laboratory for Mucosal Immunology, Johannes Kepler University, Linz, Austria
| | - Heinz Zoller
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Jan Rupp
- Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, Luebeck, Germany
| | - Stefan Schreiber
- Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
- Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Remy Burcelin
- INSERM 1297 and University Paul Sabatier: Institut des Maladies Métaboliques et Cardiovasculaires, France and Université Paul Sabatier, Toulouse, France
| | - Cornelia Lass-Flörl
- Institute of Hygiene and Medical Microbiology, ECMM, Medical University of Innsbruck, Innsbruck, Austria
| | - Zlatko Trajanoski
- Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria
| | - Georg Oberhuber
- INNPATH, Institute of Pathology, University Hospital of Innsbruck, Innsbruck, Austria
| | - Philip Rosenstiel
- Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
| | - Timon E Adolph
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| | - Konrad Aden
- Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
- Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Herbert Tilg
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria
| |
Collapse
|
5
|
Milbank E, Díaz-Trelles R, Dragano N, Latorre J, Mukthavaram R, Mayneris-Perxachs J, Ortega F, Federici M, Burcelin R, Karmali PP, Tachikawa K, Chivukula P, López M, Fernández-Real JM, Moreno-Navarrete JM. Liver lipopolysaccharide binding protein prevents hepatic inflammation in physiological and pathological non-obesogenic conditions. Pharmacol Res 2023; 187:106562. [PMID: 36410673 DOI: 10.1016/j.phrs.2022.106562] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 11/09/2022] [Accepted: 11/16/2022] [Indexed: 11/23/2022]
Abstract
Lipopolysaccharide binding protein (LBP) knockout mice models are protected against the deleterious effects of major acute inflammation but its possible physiological role has been less well studied. We aimed to evaluate the impact of liver LBP downregulation (using nanoparticles containing siRNA- Lbp) on liver steatosis, inflammation and fibrosis during a standard chow diet (STD), and in pathological non-obesogenic conditions, under a methionine and choline deficient diet (MCD, 5 weeks). Under STD, liver Lbp gene knockdown led to a significant increase in gene expression markers of liver inflammation (Itgax, Tlr4, Ccr2, Ccl2 and Tnf), liver injury (Krt18 and Crp), fibrosis (Col4a1, Col1a2 and Tgfb1), endoplasmic reticulum (ER) stress (Atf6, Hspa5 and Eif2ak3) and protein carbonyl levels. As expected, the MCD increased hepatocyte vacuolation, liver inflammation and fibrosis markers, also increasing liver Lbp mRNA. In this model, liver Lbp gene knockdown resulted in a pronounced worsening of the markers of liver inflammation (also including CD68 and MPO activity), fibrosis, ER stress and protein carbonyl levels, all indicative of non-alcoholic steatohepatitis (NASH) progression. At cellular level, Lbp gene knockdown also increased expression of the proinflammatory mediators (Il6, Ccl2), and markers of fibrosis (Col1a1, Tgfb1) and protein carbonyl levels. In agreement with these findings, liver LBP mRNA in humans positively correlated with markers of liver damage (circulating hsCRP, ALT activity, liver CRP and KRT18 gene expression), and with a network of genes involved in liver inflammation, innate and adaptive immune system, endoplasmic reticulum stress and neutrophil degranulation (all with q-value<0.05). In conclusion, current findings suggest that a significant downregulation in liver LBP levels promotes liver oxidative stress and inflammation, aggravating NASH progression, in physiological and pathological non-obesogenic conditions.
Collapse
Affiliation(s)
- Edward Milbank
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | | | - Nathalia Dragano
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Jèssica Latorre
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | | | - Jordi Mayneris-Perxachs
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Francisco Ortega
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Massimo Federici
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, Rome, Italy
| | - Remy Burcelin
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université Paul Sabatier, Toulouse, France
| | | | | | | | - Miguel López
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - José Manuel Fernández-Real
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain; Department of Medicine, University of Girona, Girona, Spain.
| | - José María Moreno-Navarrete
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain; Department of Medicine, University of Girona, Girona, Spain.
| |
Collapse
|
6
|
Smati S, Polizzi A, Fougerat A, Ellero-Simatos S, Blum Y, Lippi Y, Régnier M, Laroyenne A, Huillet M, Arif M, Zhang C, Lasserre F, Marrot A, Al Saati T, Wan J, Sommer C, Naylies C, Batut A, Lukowicz C, Fougeray T, Tramunt B, Dubot P, Smith L, Bertrand-Michel J, Hennuyer N, Pradere JP, Staels B, Burcelin R, Lenfant F, Arnal JF, Levade T, Gamet-Payrastre L, Lagarrigue S, Loiseau N, Lotersztajn S, Postic C, Wahli W, Bureau C, Guillaume M, Mardinoglu A, Montagner A, Gourdy P, Guillou H. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. Gut 2022; 71:807-821. [PMID: 33903148 DOI: 10.1136/gutjnl-2020-323323] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Revised: 03/28/2021] [Accepted: 04/09/2021] [Indexed: 12/20/2022]
Abstract
OBJECTIVE We evaluated the influence of sex on the pathophysiology of non-alcoholic fatty liver disease (NAFLD). We investigated diet-induced phenotypic responses to define sex-specific regulation between healthy liver and NAFLD to identify influential pathways in different preclinical murine models and their relevance in humans. DESIGN Different models of diet-induced NAFLD (high-fat diet, choline-deficient high-fat diet, Western diet or Western diet supplemented with fructose and glucose in drinking water) were compared with a control diet in male and female mice. We performed metabolic phenotyping, including plasma biochemistry and liver histology, untargeted large-scale approaches (liver metabolome, lipidome and transcriptome), gene expression profiling and network analysis to identify sex-specific pathways in the mouse liver. RESULTS The different diets induced sex-specific responses that illustrated an increased susceptibility to NAFLD in male mice. The most severe lipid accumulation and inflammation/fibrosis occurred in males receiving the high-fat diet and Western diet, respectively. Sex-biased hepatic gene signatures were identified for these different dietary challenges. The peroxisome proliferator-activated receptor α (PPARα) co-expression network was identified as sexually dimorphic, and in vivo experiments in mice demonstrated that hepatocyte PPARα determines a sex-specific response to fasting and treatment with pemafibrate, a selective PPARα agonist. Liver molecular signatures in humans also provided evidence of sexually dimorphic gene expression profiles and the sex-specific co-expression network for PPARα. CONCLUSIONS These findings underscore the sex specificity of NAFLD pathophysiology in preclinical studies and identify PPARα as a pivotal, sexually dimorphic, pharmacological target. TRIAL REGISTRATION NUMBER NCT02390232.
Collapse
Affiliation(s)
- Sarra Smati
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.,Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Arnaud Polizzi
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Anne Fougerat
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Sandrine Ellero-Simatos
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Yuna Blum
- CIT, Ligue Nationale Contre Le Cancer, Paris, France.,IGDR UMR 6290, CNRS, Université de Rennes 1, Rennes, France
| | - Yannick Lippi
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Marion Régnier
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Alexia Laroyenne
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Marine Huillet
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Muhammad Arif
- Science for Life Laboratory, KTH-Royal Institute of Technology, Solna, Sweden
| | - Cheng Zhang
- Science for Life Laboratory, KTH-Royal Institute of Technology, Solna, Sweden
| | - Frederic Lasserre
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Alain Marrot
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Talal Al Saati
- Experimental Histopathology Department, INSERM US006-CREFRE, University Hospital of Toulouse, Toulouse, France
| | - JingHong Wan
- INSERM-UMR1149, Centre de Recherche sur l'Inflammation, Paris, France.,Sorbonne Paris Cité, Laboratoire d'Excellence Inflamex, Faculté de Médecine, Site Xavier Bichat, Université Paris Diderot, Paris, France
| | - Caroline Sommer
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Claire Naylies
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Aurelie Batut
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Celine Lukowicz
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Tiffany Fougeray
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Blandine Tramunt
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Patricia Dubot
- Laboratoire de Biochimie Métabolique, CHU Toulouse, Toulouse, France.,INSERM U1037, CRCT, Université Paul Sabatier, Toulouse, France
| | - Lorraine Smith
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Justine Bertrand-Michel
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Nathalie Hennuyer
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France
| | - Jean-Philippe Pradere
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Bart Staels
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France
| | - Remy Burcelin
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Françoise Lenfant
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Jean-François Arnal
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Thierry Levade
- Laboratoire de Biochimie Métabolique, CHU Toulouse, Toulouse, France.,INSERM U1037, CRCT, Université Paul Sabatier, Toulouse, France
| | - Laurence Gamet-Payrastre
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | | | - Nicolas Loiseau
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| | - Sophie Lotersztajn
- INSERM-UMR1149, Centre de Recherche sur l'Inflammation, Paris, France.,Sorbonne Paris Cité, Laboratoire d'Excellence Inflamex, Faculté de Médecine, Site Xavier Bichat, Université Paris Diderot, Paris, France
| | - Catherine Postic
- Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France
| | - Walter Wahli
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.,Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.,Center for Integrative Genomics, University of Lausanne, Le Génopode, Lausanne, Switzerland
| | - Christophe Bureau
- Hepatology Unit, Rangueil Hospital Toulouse, Paul Sabatier University Toulouse 3, Toulouse, France
| | - Maeva Guillaume
- Hepatology Unit, Rangueil Hospital Toulouse, Paul Sabatier University Toulouse 3, Toulouse, France
| | - Adil Mardinoglu
- Science for Life Laboratory, KTH-Royal Institute of Technology, Solna, Sweden.,Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK
| | - Alexandra Montagner
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France
| | - Pierre Gourdy
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France .,Endocrinology-Diabetology-Nutrition Department, Toulouse University Hospital, Toulouse, France
| | - Hervé Guillou
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France
| |
Collapse
|
7
|
Thomas C, Minty M, Vinel A, Canceill T, Loubières P, Burcelin R, Kaddech M, Blasco-Baque V, Laurencin-Dalicieux S. Oral Microbiota: A Major Player in the Diagnosis of Systemic Diseases. Diagnostics (Basel) 2021; 11:1376. [PMID: 34441309 PMCID: PMC8391932 DOI: 10.3390/diagnostics11081376] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 07/28/2021] [Accepted: 07/28/2021] [Indexed: 02/06/2023] Open
Abstract
The oral cavity is host to a complex and diverse microbiota community which plays an important role in health and disease. Major oral infections, i.e., caries and periodontal diseases, are both responsible for and induced by oral microbiota dysbiosis. This dysbiosis is known to have an impact on other chronic systemic diseases, whether triggering or aggravating them, making the oral microbiota a novel target in diagnosing, following, and treating systemic diseases. In this review, we summarize the major roles that oral microbiota can play in systemic disease development and aggravation and also how novel tools can help investigate this complex ecosystem. Finally, we describe new therapeutic approaches based on oral bacterial recolonization or host modulation therapies. Collaboration in diagnosis and treatment between oral specialists and general health specialists is of key importance in bridging oral and systemic health and disease and improving patients' wellbeing.
Collapse
Affiliation(s)
- Charlotte Thomas
- INSERM UMR 1297 Inserm, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Avenue Jean Poulhès 1, CEDEX 4, 31432 Toulouse, France; (A.V.); (P.L.); (R.B.); (V.B.-B.)
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
- Service d’Odontologie Rangueil, CHU de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
| | - Matthieu Minty
- INSERM UMR 1297 Inserm, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Avenue Jean Poulhès 1, CEDEX 4, 31432 Toulouse, France; (A.V.); (P.L.); (R.B.); (V.B.-B.)
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
- Service d’Odontologie Rangueil, CHU de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
| | - Alexia Vinel
- INSERM UMR 1297 Inserm, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Avenue Jean Poulhès 1, CEDEX 4, 31432 Toulouse, France; (A.V.); (P.L.); (R.B.); (V.B.-B.)
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
- Service d’Odontologie Rangueil, CHU de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
| | - Thibault Canceill
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
- Service d’Odontologie Rangueil, CHU de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- UMR CNRS 5085, Centre Interuniversitaire de Recherche et d’Ingénierie des Matériaux (CIRIMAT), Université Paul Sabatier, 35 Chemin des Maraichers, CEDEX 9, 31062 Toulouse, France
| | - Pascale Loubières
- INSERM UMR 1297 Inserm, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Avenue Jean Poulhès 1, CEDEX 4, 31432 Toulouse, France; (A.V.); (P.L.); (R.B.); (V.B.-B.)
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
| | - Remy Burcelin
- INSERM UMR 1297 Inserm, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Avenue Jean Poulhès 1, CEDEX 4, 31432 Toulouse, France; (A.V.); (P.L.); (R.B.); (V.B.-B.)
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
| | - Myriam Kaddech
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
- Service d’Odontologie Rangueil, CHU de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
| | - Vincent Blasco-Baque
- INSERM UMR 1297 Inserm, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Avenue Jean Poulhès 1, CEDEX 4, 31432 Toulouse, France; (A.V.); (P.L.); (R.B.); (V.B.-B.)
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
- Service d’Odontologie Rangueil, CHU de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
| | - Sara Laurencin-Dalicieux
- Faculté de Chirurgie Dentaire, Université Paul Sabatier III (UPS), 118 Route de Narbonne, CEDEX 9, 31062 Toulouse, France; (T.C.); (M.K.); (S.L.-D.)
- Service d’Odontologie Rangueil, CHU de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France
- INSERM UMR 1295, Centre d’Epidémiologie et de Recherche en Santé des Populations de Toulouse (CERPOP), Epidémiologie et Analyse en Santé Publique, Risques, Maladies Chroniques et Handicaps, 37 Allées Jules Guesdes, 31000 Toulouse, France
| |
Collapse
|
8
|
Tilg H, Burcelin R, Tremaroli V. Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis? Gut 2020; 69:1373-1374. [PMID: 32060128 DOI: 10.1136/gutjnl-2019-320490] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 02/06/2020] [Accepted: 02/06/2020] [Indexed: 12/20/2022]
Affiliation(s)
- Herbert Tilg
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 1048, Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2: 'Intestinal Risk Factors, Diabetes, Dyslipidemia' F-31432, Toulouse Cedex 4, France
| | - Valentina Tremaroli
- Wallenberg Laboratory for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
9
|
Kappel BA, De Angelis L, Heiser M, Ballanti M, Stoehr R, Goettsch C, Mavilio M, Artati A, Paoluzi OA, Adamski J, Mingrone G, Staels B, Burcelin R, Monteleone G, Menghini R, Marx N, Federici M. Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. Mol Metab 2020; 36:100976. [PMID: 32251665 PMCID: PMC7183232 DOI: 10.1016/j.molmet.2020.100976] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 02/27/2020] [Accepted: 03/08/2020] [Indexed: 12/24/2022] Open
Abstract
Objective The metabolic influence of gut microbiota plays a pivotal role in the pathogenesis of cardiometabolic diseases. Antibiotics affect intestinal bacterial diversity, and long-term usage has been identified as an independent risk factor for atherosclerosis-driven events. The aim of this study was to explore the interaction between gut dysbiosis by antibiotics and metabolic pathways with the impact on atherosclerosis development. Methods We combined oral antibiotics with different diets in an Apolipoprotein E-knockout mouse model linking gut microbiota to atherosclerotic lesion development via an integrative cross-omics approach including serum metabolomics and cecal 16S rRNA targeted metagenomic sequencing. We further investigated patients with carotid atherosclerosis compared to control subjects with comparable cardiovascular risk. Results Here, we show that increased atherosclerosis by antibiotics was connected to a loss of intestinal diversity and alterations of microbial metabolic functional capacity with a major impact on the host serum metabolome. Pathways that were modulated by antibiotics and connected to atherosclerosis included diminished tryptophan and disturbed lipid metabolism. These pathways were related to the reduction of certain members of Bacteroidetes and Clostridia by antibiotics in the gut. Patients with atherosclerosis presented a similar metabolic signature as those induced by antibiotics in our mouse model. Conclusion Taken together, this work provides insights into the complex interaction between intestinal microbiota and host metabolism. Our data highlight that detrimental effects of antibiotics on the gut flora are connected to a pro-atherogenic metabolic phenotype beyond classical risk factors. Antibiotics exacerbate atherosclerosis independently of diet. Gut microbiota and metabolic alpha diversity are reduced by antibiotics. Pathways connected to atherogenesis are tryptophan and lipid metabolism. Metabolic changes are linked to reduced Clostridia and Bacteroidetes in the gut.
Collapse
Affiliation(s)
- Ben Arpad Kappel
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Department of Internal Medicine 1, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Lorenzo De Angelis
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Michael Heiser
- Metabolomic discoveries GmbH, Potsdam, Germany; Metabolon Inc., Morrisville, NC, USA
| | - Marta Ballanti
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy
| | - Robert Stoehr
- Department of Internal Medicine 1, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Claudia Goettsch
- Department of Internal Medicine 1, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Maria Mavilio
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Anna Artati
- Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | | | - Jerzy Adamski
- Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; Lehrstuhl für Experimentelle Genetik, Technical University of Munich, Freising-Weihenstephan, Germany; German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Geltrude Mingrone
- Department of Internal Medicine, Catholic University, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Diabetes and Nutritional Sciences, Hodgkin Building, Guy's Campus, King's College London, London, United Kingdom
| | - Bart Staels
- Université Lille, INSERM, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, U1011-European Genomic Institute for Diabetes, Lille, France
| | - Remy Burcelin
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Giovanni Monteleone
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Gastroenterology Unit, Policlinico Tor Vergata, Rome, Italy
| | - Rossella Menghini
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Nikolaus Marx
- Department of Internal Medicine 1, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | - Massimo Federici
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy.
| |
Collapse
|
10
|
Eddouks M, Khallouki F, Owen RW, Hebi M, Burcelin R. Evaluation of Glucose and Lipid Lowering Activity of Arganimide A in Normal and Streptozotocin-Induced Diabetic Rats. Endocr Metab Immune Disord Drug Targets 2020; 19:503-510. [PMID: 30421687 DOI: 10.2174/1871530318666181113124727] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 09/13/2018] [Accepted: 11/06/2018] [Indexed: 12/30/2022]
Abstract
AIMS Arganimide A (4,4-dihydroxy-3,3-imino-di-benzoic acid) is a compound belonging to a family of aminophenolics found in fruit of Argania spinosa. The purpose of this study was to investigate the glucose and lipid lowering activity of Arganimide A (ARG A). METHODS The effect of a single dose and daily oral administration of Arganimide A (ARG A) on blood glucose levels and plasma lipid profile was tested in normal and streptozotocin (STZ) diabetic rats at a dose of 2 mg/kg body weight. RESULTS Single oral administration of ARG A reduced blood glucose levels from 26.50±0.61 mmol/L to 14.27±0.73 mmol/L (p<0.0001) six hours after administration in STZ diabetic rats. Furthermore, blood glucose levels were decreased from 5.35±0.30 mmol/L to 3.57±0.17 mmol/L (p<0.0001) and from 26.50±0.61 mmol/L to 3.67±0.29 mmol/L (p<0.0001) in normal and STZ diabetic rats, respectively, after seven days of treatment. Moreover, no significant changes in body weight in normal and STZ rats were shown. According to the lipid profile, the plasma triglycerides levels were decreased significantly in diabetic rats after seven days of ARG treatment (p<0.05). Moreover, seven days of ARG A treatment decreased significantly the plasma cholesterol concentrations (p<0.001). CONCLUSION ARG A possesses glucose and lipid-lowering activity in diabetic rats and this natural compound may be beneficial in the treatment of diabetes.
Collapse
Affiliation(s)
- Mohamed Eddouks
- Faculty of Sciences and Techniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Farid Khallouki
- Faculty of Sciences and Techniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Robert W Owen
- Division of Preventive Oncology, National Center for Tumor Diseases, Im Neuenheimer Feld 460, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg, Germany
| | - Morad Hebi
- Faculty of Sciences and Techniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Remy Burcelin
- University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Rangueil1(2) MC, INSERM, Toulouse, France
| |
Collapse
|
11
|
Abstract
It has recently become evident that the periodontium (gingiva, desmodontal ligament, cementum and alveolar bone) and the associated microbiota play a pivotal role in regulating human health and diseases. The oral cavity is the second largest microbiota in the body with around 500 different bacterial species identified today. When disruption of oral cavity and dysbiosis occur, the proportion of strict anaerobic Gram-negative bacteria is then increased. Patients with periodontitis present 27 to 53% more risk to develop diabetes than the control population suggesting that periodontitis is an aggravating factor in the incidence of diabetes. Moreover, dysbiosis of oral microbiota is involved in both periodontal and metabolic disorders (cardiovascular diseases, dyslipidaemia …). The oral diabetic dysbiosis is characterized by a specific bacteria Porphyromonas, which is highly expressed in periodontal diseases and could exacerbate insulin resistance. In this review, we will address the nature of the oral microbiota and how it affects systemic pathologies with a bidirectional interaction. We also propose that using prebiotics like Akkermansia muciniphila may influence oral microbiota as novel therapeutic strategies. The discovery of the implication of oral microbiota for the control of metabolic diseases could be a new way for personalized medicine.
Collapse
Affiliation(s)
- Matthieu Minty
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - Thibault Canceil
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - Matteo Serino
- INSERM, INRA, ENVT, UPS, IRSD, Université de Toulouse, 31024, Toulouse, France
| | - Remy Burcelin
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - François Tercé
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France
| | - Vincent Blasco-Baque
- INSERM U1048, F-31432 Toulouse, France, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31432, Toulouse, France.
- Université Paul Sabatier III (UPS), F-31432, Toulouse, France.
- CHU Toulouse, Service d'Odontologie Toulouse, F-3100, Toulouse, France.
- INSERM UMR1048-I2MC Team 2 « Intestinal Risk Factors, Diabetes and Dyslipidemia » Building L4, 1st floor, Hospital of Rangueil 1, Avenue Jean Poulhès, 84225 31432, Toulouse Cedex 4 Lab, BP, France.
| |
Collapse
|
12
|
Abstract
The regulation of glycemia is under a tight neuronal detection of glucose levels performed by the gut-brain axis and an efficient efferent neuronal message sent to the peripheral organs, as the pancreas to induce insulin and inhibit glucagon secretions. The neuronal detection of glucose levels is performed by the autonomic nervous system including the enteric nervous system and the vagus nerve innervating the gastro-intestinal tractus, from the mouth to the anus. A dysregulation of this detection leads to the one of the most important current health issue around the world i.e. diabetes mellitus. Furthemore, the consequences of diabetes mellitus on neuronal homeostasis and activities participate to the aggravation of the disease establishing a viscious circle. Prokaryotic cells as bacteria, reside in our gut. The strong relationship between prokaryotic cells and our eukaryotic cells has been established long ago, and prokaryotic and eukaryotic cells in our body have evolved synbiotically. For the last decades, studies demonstrated the critical role of the gut microbiota on the metabolic control and how its shift can induce diseases such as diabetes. Despite an important increase of knowledge, few is known about 1) how the gut microbiota influences the neuronal detection of glucose and 2) how the diabetes mellitus-induced gut microbiota shift observed participates to the alterations of autonomic nervous system and the gut-brain axis activity.
Collapse
Affiliation(s)
- Estelle Grasset
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, 41345, Gothenburg, Sweden.
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2 : 'Intestinal Risk Factors, Diabetes, Université Paul Sabatier (UPS), Dyslipidemia', F-31432, Toulouse, Cedex 4, France
| |
Collapse
|
13
|
Ortega FJ, Moreno-Navarrete JM, Mercader JM, Gómez-Serrano M, García-Santos E, Latorre J, Lluch A, Sabater M, Caballano-Infantes E, Guzmán R, Macías-González M, Buxo M, Gironés J, Vilallonga R, Naon D, Botas P, Delgado E, Corella D, Burcelin R, Frühbeck G, Ricart W, Simó R, Castrillon-Rodríguez I, Tinahones FJ, Bosch F, Vidal-Puig A, Malagón MM, Peral B, Zorzano A, Fernández-Real JM. Cytoskeletal transgelin 2 contributes to gender-dependent adipose tissue expandability and immune function. FASEB J 2019; 33:9656-9671. [PMID: 31145872 DOI: 10.1096/fj.201900479r] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
During adipogenesis, preadipocytes' cytoskeleton reorganizes in parallel with lipid accumulation. Failure to do so may impact the ability of adipose tissue (AT) to shift between lipid storage and mobilization. Here, we identify cytoskeletal transgelin 2 (TAGLN2) as a protein expressed in AT and associated with obesity and inflammation, being normalized upon weight loss. TAGLN2 was primarily found in the adipose stromovascular cell fraction, but inflammation, TGF-β, and estradiol also prompted increased expression in human adipocytes. Tagln2 knockdown revealed a key functional role, being required for proliferation and differentiation of fat cells, whereas transgenic mice overexpressing Tagln2 using the adipocyte protein 2 promoter disclosed remarkable sex-dependent variations, in which females displayed "healthy" obesity and hypertrophied adipocytes but preserved insulin sensitivity, and males exhibited physiologic changes suggestive of defective AT expandability, including increased number of small adipocytes, activation of immune cells, mitochondrial dysfunction, and impaired metabolism together with decreased insulin sensitivity. The metabolic relevance and sexual dimorphism of TAGLN2 was also outlined by genetic variants that may modulate its expression and are associated with obesity and the risk of ischemic heart disease in men. Collectively, current findings highlight the contribution of cytoskeletal TAGLN2 to the obese phenotype in a gender-dependent manner.-Ortega, F. J., Moreno-Navarrete, J. M., Mercader, J. M., Gómez-Serrano, M., García-Santos, E., Latorre, J., Lluch, A., Sabater, M., Caballano-Infantes, E., Guzmán, R., Macías-González, M., Buxo, M., Gironés, J., Vilallonga, R., Naon, D., Botas, P., Delgado, E., Corella, D., Burcelin, R., Frühbeck, G., Ricart, W., Simó, R., Castrillon-Rodríguez, I., Tinahones, F. J., Bosch, F., Vidal-Puig, A., Malagón, M. M., Peral, B., Zorzano, A., Fernández-Real, J. M. Cytoskeletal transgelin 2 contributes to gender-dependent adipose tissue expandability and immune function.
Collapse
Affiliation(s)
- Francisco J Ortega
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - José M Moreno-Navarrete
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Josep M Mercader
- Barcelona Supercomputing Center (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain
| | - María Gómez-Serrano
- Department of Endocrinology, Physiopathology, and Nervous System, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Eva García-Santos
- Department of Endocrinology, Physiopathology, and Nervous System, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Jèssica Latorre
- Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Aina Lluch
- Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Mònica Sabater
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Estefanía Caballano-Infantes
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Rocío Guzmán
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-University of Cordoba-Reina Sofia University Hospital, Córdoba, Spain
| | - Manuel Macías-González
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Service of Endocrinology and Nutrition, Hospital Clínico Universitario Virgen de Victoria de Malaga, Málaga, Spain
| | - Maria Buxo
- Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Jordi Gironés
- Department of Surgery, Institut d'Investigació Biomédica de Girona (IdIBGi), Girona, Spain
| | - Ramon Vilallonga
- Servicio de Cirugía General, Unidad de Cirugía Endocrina, Bariátrica y Metabólica, Hospital Universitario Vall d'Hebron, European Center of Excellence (EAC-BS), Barcelona, Spain
| | - Deborah Naon
- Departament de Bioquímica i Biología Molecular, Facultat de Biología, Institute for Research in Biomedicine (IRB Barcelona), Universitat de Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Patricia Botas
- Department of Medicine, University of Oviedo Endocrinology and Nutrition Service, Hospital Universitario Central de Asturias (HUCA) and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Elias Delgado
- Department of Medicine, University of Oviedo Endocrinology and Nutrition Service, Hospital Universitario Central de Asturias (HUCA) and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Dolores Corella
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Preventive Medicine and Public Health, Genetic and Molecular Epidemiology Unit, School of Medicine, University of Valencia, Valencia, Spain
| | - Remy Burcelin
- INSERM Unité 858, IFR31, Institut de Médecine Moléculaire de Rangueil, Université Paul Sabatier, Toulouse, France
| | - Gema Frühbeck
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Endocrinology and Nutrition, Clínica Universidad de Navarra (IdiSNA), Pamplona, Spain
| | - Wifredo Ricart
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Rafael Simó
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain
| | - Ignacio Castrillon-Rodríguez
- Departament de Bioquímica i Biología Molecular, Facultat de Biología, Institute for Research in Biomedicine (IRB Barcelona), Universitat de Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Francisco J Tinahones
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Service of Endocrinology and Nutrition, Hospital Clínico Universitario Virgen de Victoria de Malaga, Málaga, Spain
| | - Fátima Bosch
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Biochemistry and Molecular Biology, Centre of Animal Biotechnology and Gene Therapy, School of Veterinary Medicine, Autonomous University of Barcelona, Barcelona, Spain
| | - Antonio Vidal-Puig
- Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - María M Malagón
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-University of Cordoba-Reina Sofia University Hospital, Córdoba, Spain
| | - Belén Peral
- Department of Endocrinology, Physiopathology, and Nervous System, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Antonio Zorzano
- Departament de Bioquímica i Biología Molecular, Facultat de Biología, Institute for Research in Biomedicine (IRB Barcelona), Universitat de Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - José M Fernández-Real
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Diabetes, Endocrinology, and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| |
Collapse
|
14
|
Zhang-Sun W, Tercé F, Burcelin R, Novikov A, Serino M, Caroff M. Structure function relationships in three lipids A from the Ralstonia genus rising in obese patients. Biochimie 2019; 159:72-80. [PMID: 30703476 DOI: 10.1016/j.biochi.2019.01.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 01/22/2019] [Indexed: 10/27/2022]
Abstract
The identification of a functional molecular moiety relating the lipopolysaccharides (LPSs) to their capacity to induce inflammation-mediated metabolic diseases needed to be performed. We previously described a proportional increase in the relative abundance of the 16 SrDNA bacterial gene from the genus Ralstonia, within the microbiota from the adipose tissue stroma vascular fraction of obese patients, suggesting a causal role of the bacteria. Therefore, we first characterized the structures of the lipids A, the inflammatory inducing moieties of LPSs, of three Ralstonia species: Ralstonia eutropha, R. mannitolilytica and R. pickettii, and then compared each, in terms of in vitro inflammatory capacities. R. pickettii lipid A displaying only 5 Fatty Acids (FA) was a weaker inducer of inflammation, compared to the two other species harboring hexa-acylated lipids A, despite the presence of 2 AraN substituents on the phosphate groups. With regard to in vitro pro-inflammatory activities, TNF-α and IL-6 inducing capacities were compared on THP-1 cells treated with LPSs isolated from the three Ralstonia. R. pickettii, with low inflammatory capacities, and recently involved in nosocomial outcomes, could explain the low inflammatory level reported in previous studies on diabetic patients and animals. In addition, transmission electron microscopy was performed on the three Ralstonia species. It showed that the R. pickettii under-acylated LPSs, with a higher level of phosphate substitution had the capacity of producing more outer membrane vesicles (OMVs). The latter could facilitate transfer of LPSs to the blood and explain the increased low-grade inflammation observed in obese/diabetic patients.
Collapse
Affiliation(s)
- Wei Zhang-Sun
- I2BC, Centre National de la Recherche Scientifique, Université de Paris-Sud, Université de Paris-Saclay, Orsay, France
| | - François Tercé
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil I(2)MC, INSERM, Toulouse, France
| | - Remy Burcelin
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil I(2)MC, INSERM, Toulouse, France
| | - Alexey Novikov
- LPS-BioSciences, I2BC, Bâtiment 409, Université de Paris-Sud, Orsay, France
| | - Matteo Serino
- Université de Toulouse, UPS, Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil I(2)MC, INSERM, Toulouse, France
| | - Martine Caroff
- I2BC, Centre National de la Recherche Scientifique, Université de Paris-Sud, Université de Paris-Saclay, Orsay, France; LPS-BioSciences, I2BC, Bâtiment 409, Université de Paris-Sud, Orsay, France.
| |
Collapse
|
15
|
van den Elsen LWJ, Garssen J, Burcelin R, Verhasselt V. Shaping the Gut Microbiota by Breastfeeding: The Gateway to Allergy Prevention? Front Pediatr 2019; 7:47. [PMID: 30873394 PMCID: PMC6400986 DOI: 10.3389/fped.2019.00047] [Citation(s) in RCA: 141] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 02/04/2019] [Indexed: 12/23/2022] Open
Abstract
Evidence is accumulating that demonstrates the importance of the gut microbiota in health and diseases such as allergy. Recent studies emphasize the importance of the "window of opportunity" in early life, during which interventions altering the gut microbiota induce long-term effects. The neonate's gut microbiota composition and metabolism could therefore play an essential role in allergic disease risk. Breastfeeding shapes the gut microbiota in early life, both directly by exposure of the neonate to the milk microbiota and indirectly, via maternal milk factors that affect bacterial growth and metabolism such as human milk oligosaccharides, secretory IgA, and anti-microbial factors. The potential of breastmilk to modulate the offspring's early gut microbiota is a promising tool for allergy prevention. Here, we will review the existing evidence demonstrating the impact of breastfeeding on shaping the neonate's gut microbiota and highlight the potential of this strategy for allergy prevention.
Collapse
Affiliation(s)
| | - Johan Garssen
- Division of Pharmacology, Faculty of Science, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Valerie Verhasselt
- School of Molecular Sciences, University of Western Australia, Perth, WA, Australia
| |
Collapse
|
16
|
Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, Sovran B, Denis RGP, Dairou J, Cardellini M, Moreno-Navarrete JM, Straub M, Jegou S, McQuitty C, Viel T, Esposito B, Tavitian B, Callebert J, Luquet SH, Federici M, Fernandez-Real JM, Burcelin R, Launay JM, Tedgui A, Mallat Z, Sokol H, Taleb S. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med 2018; 24:1113-1120. [PMID: 29942089 DOI: 10.1038/s41591-018-0060-4] [Citation(s) in RCA: 171] [Impact Index Per Article: 28.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 04/23/2018] [Indexed: 02/07/2023]
Abstract
The association between altered gut microbiota, intestinal permeability, inflammation and cardiometabolic diseases is becoming increasingly clear but remains poorly understood1,2. Indoleamine 2,3-dioxygenase is an enzyme induced in many types of immune cells, including macrophages in response to inflammatory stimuli, and catalyzes the degradation of tryptophan along the kynurenine pathway. Indoleamine 2,3-dioxygenase activity is better known for its suppression of effector T cell immunity and its activation of regulatory T cells3,4. However, high indoleamine 2,3-dioxygenase activity predicts worse cardiovascular outcome5-9 and may promote atherosclerosis and vascular inflammation6, suggesting a more complex role in chronic inflammatory settings. Indoleamine 2,3-dioxygenase activity is also increased in obesity10-13, yet its role in metabolic disease is still unexplored. Here, we show that obesity is associated with an increase of intestinal indoleamine 2,3-dioxygenase activity, which shifts tryptophan metabolism from indole derivative and interleukin-22 production toward kynurenine production. Indoleamine 2,3-dioxygenase deletion or inhibition improves insulin sensitivity, preserves the gut mucosal barrier, decreases endotoxemia and chronic inflammation, and regulates lipid metabolism in liver and adipose tissues. These beneficial effects are due to rewiring of tryptophan metabolism toward a microbiota-dependent production of interleukin-22 and are abrogated after treatment with a neutralizing anti-interleukin-22 antibody. In summary, we identify an unexpected function of indoleamine 2,3-dioxygenase in the fine tuning of intestinal tryptophan metabolism with major consequences on microbiota-dependent control of metabolic disease, which suggests indoleamine 2,3-dioxygenase as a potential therapeutic target.
Collapse
Affiliation(s)
- Ludivine Laurans
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Nicolas Venteclef
- Institut National de la Santé et de la Recherche Médicale, UMRS 1138, Sorbonne Universités, UPMC Université Paris 06, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, and Centre de Recherche des Cordeliers, Paris, France
| | - Yacine Haddad
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Mouna Chajadine
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Fawaz Alzaid
- Institut National de la Santé et de la Recherche Médicale, UMRS 1138, Sorbonne Universités, UPMC Université Paris 06, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, and Centre de Recherche des Cordeliers, Paris, France
| | - Sarvenaz Metghalchi
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Bruno Sovran
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Raphael G P Denis
- Unité de Biologie Fonctionnelle et Adaptative, Centre National la Recherche Scientifique, UMR 8251, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Julien Dairou
- UMR 8601 CNRS, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Université Paris Descartes-Sorbonne Paris Cité, Paris, France
| | - Marina Cardellini
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Jose-Maria Moreno-Navarrete
- Department of Diabetes and Endocrinology, Hospital de Girona "Dr Josep Trueta", Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain
| | - Marjolene Straub
- Sorbonne Université, École normale supérieure, PSL Research University, CNRS, INSERM, AP-HP, Laboratoire de biomolécules, Hôpital Saint-Antoine, Paris, France
| | - Sarah Jegou
- Sorbonne Université, École normale supérieure, PSL Research University, CNRS, INSERM, AP-HP, Laboratoire de biomolécules, Hôpital Saint-Antoine, Paris, France
| | - Claire McQuitty
- Sorbonne Université, École normale supérieure, PSL Research University, CNRS, INSERM, AP-HP, Laboratoire de biomolécules, Hôpital Saint-Antoine, Paris, France
| | - Thomas Viel
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Bruno Esposito
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Bertrand Tavitian
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Jacques Callebert
- Service de Biochimie, Assistance Publique Hôpitaux de Paris, and INSERM UMR942, Hôpital Lariboisière, Paris, France
| | - Serge H Luquet
- Unité de Biologie Fonctionnelle et Adaptative, Centre National la Recherche Scientifique, UMR 8251, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Massimo Federici
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | | | - Remy Burcelin
- Institut des maladies métaboliques et cardiovasculaires, INSERM UMR1048, Toulouse, France
| | - Jean-Marie Launay
- Service de Biochimie, Assistance Publique Hôpitaux de Paris, and INSERM UMR942, Hôpital Lariboisière, Paris, France
| | - Alain Tedgui
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
| | - Ziad Mallat
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France
- Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
| | - Harry Sokol
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
- Sorbonne Université, École normale supérieure, PSL Research University, CNRS, INSERM, AP-HP, Laboratoire de biomolécules, Hôpital Saint-Antoine, Paris, France
- Department of Gastroenterology, Saint Antoine Hospital, Assistance Publique - Hopitaux de Paris, Sorbonne Université, Paris, France
| | - Soraya Taleb
- Institut National de la Santé et de la Recherche Médicale, U970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France.
| |
Collapse
|
17
|
Serino M, Nicolas S, Trabelsi MS, Burcelin R, Blasco-Baque V. Young microbes for adult obesity. Pediatr Obes 2017; 12:e28-e32. [PMID: 27135640 DOI: 10.1111/ijpo.12146] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Revised: 03/23/2016] [Accepted: 03/25/2016] [Indexed: 12/20/2022]
Abstract
Gut microbes are active participants of host metabolism. At birth, child physiology is committed towards healthiness or sickness depending, in part, on maternal condition (i.e. lean vs obesity) and delivery. Finally, changes from breastfeeding to solid food also account to define gut microbiota ecology in adulthood. Nowadays, alterations of gut microbiota, named dysbiosis, are acquired risk factors for multiple diseases, especially type 2 diabetes and obesity. Despite important evidence linking nutrition to dysbiosis to energetic dysmetabolism, molecular mechanisms for causality are still missing. That the status of gut microbiota of mother and child is crucial for future diseases is witnessed by adulthood overweight and obesity observed in children with dysbiosis. In this short review we highlight the importance of early life events related to the microbiota and their impact on future adult disease risk. Therefore, our effort to treat or prevent metabolic diseases should be addressed towards early or previous life steps, when microbial decisions are going to affect our metabolic fate.
Collapse
Affiliation(s)
- M Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - S Nicolas
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - M-S Trabelsi
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - R Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
| | - V Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France.,L.U. 51 « Parodontites et Maladies Générales », Université Paul Sabatier, Faculté de Chirurgie Dentaire, Toulouse, France
| |
Collapse
|
18
|
Luche E, Robert V, Cuminetti V, Pomié C, Sastourné-Arrey Q, Waget A, Arnaud E, Varin A, Labit E, Laharrague P, Burcelin R, Casteilla L, Cousin B. Corrupted adipose tissue endogenous myelopoiesis initiates diet-induced metabolic disease. eLife 2017; 6. [PMID: 28656887 PMCID: PMC5509432 DOI: 10.7554/elife.23194] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 06/28/2017] [Indexed: 12/21/2022] Open
Abstract
Activation and increased numbers of inflammatory macrophages, in adipose tissue (AT) are deleterious in metabolic diseases. Up to now, AT macrophages (ATM) accumulation was considered to be due to blood infiltration or local proliferation, although the presence of resident hematopoietic stem/progenitor cells (Lin-/Sca+/c-Kit+; LSK phenotype) in the AT (AT-LSK) has been reported. By using transplantation of sorted AT-LSK and gain and loss of function studies we show that some of the inflammatory ATM inducing metabolic disease, originate from resident AT-LSK. Transplantation of AT-LSK sorted from high fat diet-fed (HFD) mice is sufficient to induce ATM accumulation, and to transfer metabolic disease in control mice. Conversely, the transplantation of control AT-LSK improves both AT-inflammation and glucose homeostasis in HFD mice. Our results clearly demonstrate that resident AT-LSK are one of the key point of metabolic disease, and could thus constitute a new promising therapeutic target to fight against metabolic disease. DOI:http://dx.doi.org/10.7554/eLife.23194.001
Collapse
Affiliation(s)
- Elodie Luche
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Virginie Robert
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Vincent Cuminetti
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Celine Pomié
- INSERM U1048, Université de Toulouse, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Quentin Sastourné-Arrey
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Aurélie Waget
- INSERM U1048, Université de Toulouse, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Emmanuelle Arnaud
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Audrey Varin
- STROMALab, Université de Toulouse, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Elodie Labit
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Patrick Laharrague
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Remy Burcelin
- INSERM U1048, Université de Toulouse, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Louis Casteilla
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| | - Beatrice Cousin
- STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
| |
Collapse
|
19
|
Nicolas S, Blasco-Baque V, Fournel A, Gilleron J, Klopp P, Waget A, Ceppo F, Marlin A, Padmanabhan R, Iacovoni JS, Tercé F, Cani PD, Tanti JF, Burcelin R, Knauf C, Cormont M, Serino M. Transfer of dysbiotic gut microbiota has beneficial effects on host liver metabolism. Mol Syst Biol 2017; 13:921. [PMID: 28302863 PMCID: PMC5371731 DOI: 10.15252/msb.20167356] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Gut microbiota dysbiosis has been implicated in a variety of systemic disorders, notably metabolic diseases including obesity and impaired liver function, but the underlying mechanisms are uncertain. To investigate this question, we transferred caecal microbiota from either obese or lean mice to antibiotic-free, conventional wild-type mice. We found that transferring obese-mouse gut microbiota to mice on normal chow (NC) acutely reduces markers of hepatic gluconeogenesis with decreased hepatic PEPCK activity, compared to non-inoculated mice, a phenotypic trait blunted in conventional NOD2 KO mice. Furthermore, transferring of obese-mouse microbiota changes both the gut microbiota and the microbiome of recipient mice. We also found that transferring obese gut microbiota to NC-fed mice then fed with a high-fat diet (HFD) acutely impacts hepatic metabolism and prevents HFD-increased hepatic gluconeogenesis compared to non-inoculated mice. Moreover, the recipient mice exhibit reduced hepatic PEPCK and G6Pase activity, fed glycaemia and adiposity. Conversely, transfer of lean-mouse microbiota does not affect markers of hepatic gluconeogenesis. Our findings provide a new perspective on gut microbiota dysbiosis, potentially useful to better understand the aetiology of metabolic diseases.
Collapse
Affiliation(s)
- Simon Nicolas
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France.,Faculté de Chirurgie Dentaire de Toulouse, Université Paul Sabatier, Toulouse Cedex, France
| | - Audren Fournel
- Toulouse III, Institut de Recherche en Santé Digestive (IRSD) Team 3, "Intestinal Neuroimmune Interactions" INSERM U1220, Université Paul Sabatier, Toulouse Cedex 3, France.,European Associated Laboratory NeuroMicrobiota (INSERM/UCL), Bâtiment B - Pavillon Lefebvre, Toulouse Cedex 3, France
| | - Jerome Gilleron
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Pascale Klopp
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Aurelie Waget
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Franck Ceppo
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Alysson Marlin
- Toulouse III, Institut de Recherche en Santé Digestive (IRSD) Team 3, "Intestinal Neuroimmune Interactions" INSERM U1220, Université Paul Sabatier, Toulouse Cedex 3, France.,European Associated Laboratory NeuroMicrobiota (INSERM/UCL), Bâtiment B - Pavillon Lefebvre, Toulouse Cedex 3, France
| | - Roshan Padmanabhan
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Jason S Iacovoni
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - François Tercé
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Patrice D Cani
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
| | - Jean-François Tanti
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| | - Claude Knauf
- Toulouse III, Institut de Recherche en Santé Digestive (IRSD) Team 3, "Intestinal Neuroimmune Interactions" INSERM U1220, Université Paul Sabatier, Toulouse Cedex 3, France.,European Associated Laboratory NeuroMicrobiota (INSERM/UCL), Bâtiment B - Pavillon Lefebvre, Toulouse Cedex 3, France
| | - Mireille Cormont
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France .,Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (I2MC), Université Paul Sabatier (UPS), Toulouse Cedex 4, France
| |
Collapse
|
20
|
Eddouks M, Lemhadri A, Hebi M, EL Hidani A, Zeggwagh NA, EL Bouhali B, Hajji L, Burcelin R. Capparis spinosa L. aqueous extract evokes antidiabetic effect in streptozotocin-induced diabetic mice. Avicenna J Phytomed 2017; 7:191-198. [PMID: 28348974 PMCID: PMC5355824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE As the aqueous extract of Capparis spinosa (CS) possess antidiabetic effect, he present study aims to reveal the possible mechanism of action of CS in diabetic mice. MATERIALS AND METHODS Both single and repeated oral administrations of aqueous extract of CS were performed in multi-low dose streptozotocin-induced (MLDS) diabetic mice. Euglycemic hyperinsulinemic clamp was used in association with the endogenous glucose production (perfusion rate of 3-3H glucose) to evaluate the effect of CS aqueous extract on insulin sensitivity. RESULTS Our study showed that aqueous extract of CS possess a potent hypoglycaemic activity in MLDS diabetic mice. Furthermore, the analysis perfusion of 3-3H glucose demonstrated the parallel decrease of basal endogenous glucose production (EGP) with the hypoglycaemic activity. EGP was lower in CS-Treated group when compared to the control group (p<0.001). The euglycemic hyperinsulinemic clamp technique demonstrated that CS treatment improves insulin sensitivity in peripheral tissues. CONCLUSION We conclude that the antihyperglycemic effet CS is probably due to the inhibition of basal endogenous glucose production and the improvement of insulin sensitivity in MLDS diabetic mice.
Collapse
Affiliation(s)
- Mohamed Eddouks
- Faculty of Sciences and Tecniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco,Corresponding Author: Tel: +212 35 57 44 97, Fax: +212 35 57 44 85,
| | - Ahmed Lemhadri
- Faculty of Sciences and Tecniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Morad Hebi
- Faculty of Sciences and Tecniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Ahmed EL Hidani
- Faculty of Sciences and Tecniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Naoufel Ali Zeggwagh
- Faculty of Sciences and Tecniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco,ISPITS Rabat, Avenue Hassan II Km 4,5 Route de Casa, Rabat Maroc
| | - Bachir EL Bouhali
- Faculty of Sciences and Tecniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Lhoussaine Hajji
- Faculty of Sciences and Tecniques Errachidia, Moulay Ismail University, BP 509, Boutalamine, Errachidia, 52000, Morocco
| | - Remy Burcelin
- UMR 5018 CNRS-UPS and IFR 31, Rangueil Hospital, L1 Bldg, BP 84225 Toulouse 31432 Cedex 4, France
| |
Collapse
|
21
|
Burcelin R, Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Obes Rev 2017; 18:86-98. [PMID: 27636208 DOI: 10.1111/obr.12465] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Revised: 08/01/2016] [Accepted: 08/01/2016] [Indexed: 01/07/2023]
Abstract
Over the past 30 years, there has been a dramatic rise in global obesity prevalence, resulting in significant economic and social consequences. Attempts to develop pharmacological agents to treat obesity have met with many obstacles including the lack of long-term effectiveness and the potential for adverse effects. Historically, there have been limited treatment options for overweight and obesity; however, since 2012, a number of new drugs have become available. A number of peptides produced in the gut act as key mediators of the gut-brain axis, which is involved in appetite regulation. This review discusses the role of the gut-brain axis in appetite regulation with special focus on glucagon-like peptide-1. Liraglutide 3.0 mg, a glucagon-like peptide-1 receptor agonist that targets this pathway, is now approved for the treatment of obesity and overweight (body mass index ≥27 kg/m2 ) with comorbidities such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. In addition, other glucagon-like peptide-1 receptor agonists offer promise for obesity management in the future. This review examines how glucagon-like peptide-1 receptor agonists promote weight loss and summarizes the clinical data on weight loss with glucagon-like peptide-1 receptor agonists.
Collapse
Affiliation(s)
- R Burcelin
- Inserm U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France
| | - P Gourdy
- Inserm U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France.,Diabetology Department, Toulouse University Hospital, Toulouse, France
| |
Collapse
|
22
|
Mavilio M, Marchetti V, Fabrizi M, Stöhr R, Marino A, Casagrande V, Fiorentino L, Cardellini M, Kappel B, Monteleone I, Garret C, Mauriello A, Monteleone G, Farcomeni A, Burcelin R, Menghini R, Federici M. A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction. Cell Rep 2016; 16:2269. [PMID: 27558826 DOI: 10.1016/j.celrep.2016.07.078] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
23
|
Mavilio M, Marchetti V, Fabrizi M, Stöhr R, Marino A, Casagrande V, Fiorentino L, Cardellini M, Kappel B, Monteleone I, Garret C, Mauriello A, Monteleone G, Farcomeni A, Burcelin R, Menghini R, Federici M. A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction. Cell Rep 2016; 16:731-43. [PMID: 27373162 DOI: 10.1016/j.celrep.2016.06.027] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 03/23/2016] [Accepted: 06/03/2016] [Indexed: 01/09/2023] Open
Abstract
The effect of gut microbiota on obesity and insulin resistance is now recognized, but the underlying host-dependent mechanisms remain poorly undefined. We find that tissue inhibitor of metalloproteinase 3 knockout (Timp3(-/-)) mice fed a high-fat diet exhibit gut microbiota dysbiosis, an increase in branched chain and aromatic (BCAA) metabolites, liver steatosis, and an increase in circulating soluble IL-6 receptors (sIL6Rs). sIL6Rs can then activate inflammatory cells, such as CD11c(+) cells, which drive metabolic inflammation. Depleting the microbiota through antibiotic treatment significantly improves glucose tolerance, hepatic steatosis, and systemic inflammation, and neutralizing sIL6R signaling reduces inflammation, but only mildly impacts glucose tolerance. Collectively, our results suggest that gut microbiota is the primary driver of the observed metabolic dysfunction, which is mediated, in part, through IL-6 signaling. Our findings also identify an important role for Timp3 in mediating the effect of the microbiota in metabolic diseases.
Collapse
Affiliation(s)
- Maria Mavilio
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Valentina Marchetti
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Marta Fabrizi
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; Research Unit for Multi-Factorial Diseases, Obesity and Diabetes Scientific Directorate, Bambino Gesù Children Hospital, 00146 Rome, Italy
| | - Robert Stöhr
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; Department of Internal Medicine I, University Hospital Aachen, 52074 Aachen, Germany
| | - Arianna Marino
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Viviana Casagrande
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Loredana Fiorentino
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Marina Cardellini
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Ben Kappel
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; Department of Internal Medicine I, University Hospital Aachen, 52074 Aachen, Germany
| | - Ivan Monteleone
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00173 Rome, Italy
| | - Celine Garret
- INSERM U1048, Université Paul Sabatier, IMC, 31432 Toulouse, France
| | - Alessandro Mauriello
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00173 Rome, Italy
| | - Giovanni Monteleone
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Alessio Farcomeni
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00161 Rome, Italy
| | - Remy Burcelin
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00161 Rome, Italy
| | - Rossella Menghini
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Massimo Federici
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
| |
Collapse
|
24
|
Branchereau M, Reichardt F, Loubieres P, Marck P, Waget A, Azalbert V, Colom A, Padmanabhan R, Iacovoni JS, Giry A, Tercé F, Heymes C, Burcelin R, Serino M, Blasco-Baque V. Periodontal dysbiosis linked to periodontitis is associated with cardiometabolic adaptation to high-fat diet in mice. Am J Physiol Gastrointest Liver Physiol 2016; 310:G1091-101. [PMID: 27033119 DOI: 10.1152/ajpgi.00424.2015] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 03/03/2016] [Indexed: 01/31/2023]
Abstract
Periodontitis and type 2 diabetes are connected pandemic diseases, and both are risk factors for cardiovascular complications. Nevertheless, the molecular factors relating these two chronic pathologies are poorly understood. We have shown that, in response to a long-term fat-enriched diet, mice present particular gut microbiota profiles related to three metabolic phenotypes: diabetic-resistant (DR), intermediate (Inter), and diabetic-sensitive (DS). Moreover, many studies suggest that a dysbiosis of periodontal microbiota could be associated with the incidence of metabolic and cardiac diseases. We investigated whether periodontitis together with the periodontal microbiota may also be associated with these different cardiometabolic phenotypes. We report that the severity of glucose intolerance is related to the severity of periodontitis and cardiac disorders. In detail, alveolar bone loss was more accentuated in DS than Inter, DR, and normal chow-fed mice. Molecular markers of periodontal inflammation, such as TNF-α and plasminogen activator inhibitor-1 mRNA levels, correlated positively with both alveolar bone loss and glycemic index. Furthermore, the periodontal microbiota of DR mice was dominated by the Streptococcaceae family of the phylum Firmicutes, whereas the periodontal microbiota of DS mice was characterized by increased Porphyromonadaceae and Prevotellaceae families. Moreover, in DS mice the periodontal microbiota was indicated by an abundance of the genera Prevotella and Tannerella, which are major periodontal pathogens. PICRUSt analysis of the periodontal microbiome highlighted that prenyltransferase pathways follow the cardiometabolic adaptation to a high-fat diet. Finally, DS mice displayed a worse cardiac phenotype, percentage of fractional shortening, heart rhythm, and left ventricle weight-to-tibia length ratio than Inter and DR mice. Together, our data show that periodontitis combined with particular periodontal microbiota and microbiome is associated with metabolic adaptation to a high-fat diet related to the severity of cardiometabolic alteration.
Collapse
Affiliation(s)
- Maxime Branchereau
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - François Reichardt
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Pascale Loubieres
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France; Faculté de Chirurgie-Dentaire de Toulouse, Toulouse, France; and
| | - Pauline Marck
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Aurélie Waget
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Vincent Azalbert
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - André Colom
- Equipe Intéraction Mycobactériennes avec les Cellules Hôtes, Institute of Pharmacology and Structural Biology, Centre National de la Recherche Scientifique, Toulouse, France
| | - Roshan Padmanabhan
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Jason S Iacovoni
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Anaïs Giry
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - François Tercé
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Christophe Heymes
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Matteo Serino
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Vincent Blasco-Baque
- Institut National de la Santé et de la Recherche Médicale U1048 and Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Université Paul Sabatier, Toulouse, France; Faculté de Chirurgie-Dentaire de Toulouse, Toulouse, France; and
| |
Collapse
|
25
|
Abstract
Obesity is characterized by gut microbiota dysbiosis and reduced thermogenic activity of brown adipose tissue. A recent study reveals that gut microbiota hampers the emergence of thermogenic brown fat cells named beige cells within white fat depots via a mechanism that involves the control of macrophages and eosinophil infiltration.
Collapse
Affiliation(s)
- Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France; Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2 : 'Intestinal Risk Factors, Diabetes, Dyslipidemia' F-31432 Toulouse Cedex 4, France.
| | - Céline Pomié
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France; Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2 : 'Intestinal Risk Factors, Diabetes, Dyslipidemia' F-31432 Toulouse Cedex 4, France
| |
Collapse
|
26
|
Fernandez-Real JM, Serino M, Blasco G, Puig J, Daunis-i-Estadella J, Ricart W, Burcelin R, Fernández-Aranda F, Portero-Otin M. Gut Microbiota Interacts With Brain Microstructure and Function. J Clin Endocrinol Metab 2015; 100:4505-13. [PMID: 26445114 DOI: 10.1210/jc.2015-3076] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
CONTEXT Evidence from animals suggests that gut microbiota affects brain structure and function but evidence in humans is scarce. OBJECTIVE This study sought to evaluate potential interactions among gut microbiota composition, brain microstructure, and cognitive tests in obese and nonobese subjects. DESIGN, SETTING, AND PARTICIPANTS This was a cross-sectional study at a tertiary hospital including 20 consecutive obese and 19 nonobese subjects similar in age and sex. MAIN OUTCOME MEASURES Gut microbiota (16S bacterial gene pyrosequencing), brain microstructure (diffusion tensor imaging of brain white and gray matter and R2* sequences in magnetic resonance imaging) and cognitive tests. RESULTS Hierarchical clustering revealed a specific gut microbiota-brain map profile for obese individuals who could be discriminated from nonobese subjects (accuracy of 0.81). Strikingly, Shannon index was linked to R2* and fractional anisotropy of the hypothalamus, caudate nucleus, and hippocampus, suggesting sparing of these brain structures with increased bacterial biodiversity. Microbiota profile also clustered with cognitive function. The relative abundance of Actinobacteria phylum was linked not only to magnetic resonance imaging diffusion tensor imaging variables in the thalamus, hypothalamus, and amygdala but also to cognitive test scores related to speed, attention, and cognitive flexibility. CONCLUSIONS In sum, obesity status affects microbiota-brain microstructure and function crosstalk.
Collapse
Affiliation(s)
- José-Manuel Fernandez-Real
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Matteo Serino
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Gerard Blasco
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Josep Puig
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Josep Daunis-i-Estadella
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Wifredo Ricart
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Remy Burcelin
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Fernando Fernández-Aranda
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| | - Manuel Portero-Otin
- Department of Diabetes, Endocrinology and Nutrition (J.-M.F.-R., W.R.), Institut d'Investigació Biomédica de Girona, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III, Girona, 17007 Spain; Institut National de la Santé et de la Recherche Médicale (M.S., R.B.), Toulouse, France; Unité Mixte de Recherche 1048 (M.S., R.B.), Institut de Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse Cedex 4, France; Girona Biomedical Research Institute, Department of Radiology-Institut de Diagnostic per la Imatge (G.B., J.P.), Hospital Universitari Dr Josep Trueta, Girona, 17007 Spain; Department of Computer Science, Applied Mathematics, and Statistics (J.D.-E.), University of Girona, Girona, 17071 Spain; Department of Psychiatry (F.F.-A.), University Hospital of Bellvitge-IDIBELL, Barcelona, CIBERobn, Instituto Salud Carlos III, Barcelona, 08908 Spain; and Nutren Group, Department of Experimental Medicine (M.P.-O.), PCiTAL-IRBLleida-Universitat de Lleida, Lleida, 25198 Spain
| |
Collapse
|
27
|
Stenman LK, Burcelin R, Lahtinen S. Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics. Benef Microbes 2015; 7:11-22. [PMID: 26565087 DOI: 10.3920/bm2015.0069] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Changes in the gut microbiota are associated with metabolic disorders, such as overweight and elevated blood glucose. Mouse studies have shown that gut microbiota can regulate metabolism with a mechanism related to gut barrier function. An impaired gut barrier permits the translocation of bacteria and their components which, when in contact with the sub-mucosal immune system, evoke metabolic inflammation and distract signalling in metabolically active tissues. Despite thorough research of the topic in animals, the hypothesis is yet to be proven in humans. Cross-sectional studies have shown that certain bacterial populations - such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Methanobrevibacter smithii and Christensenellaceae - are better represented in lean individuals compared to those who are overweight or metabolically unhealthy. Although these differences reflect those seen in mice, it is possible that they are caused by different dietary or other lifestyle habits. Diet has an indisputable influence on gut microbiota making it very difficult to draw conclusions on microbiota-host interactions from cross-sectional studies. Certain research areas do, however, indicate that gut microbiota could causally influence metabolism. Several studies show that antibiotic use in infancy increases body weight in later childhood. Also, probiotics are emerging as a potential therapy for metabolic syndrome. In fact, a handful of human studies and numerous animal studies show promise for probiotics in reducing blood glucose levels or improving insulin sensitivity. For weight management human evidence is scarcer. Nevertheless, it is becoming increasingly recognised that gut microbiota plays a part regulating metabolism, also in humans, which gives rise to novel opportunities for preventative and treatment strategies.
Collapse
Affiliation(s)
- L K Stenman
- 1 DuPont Nutrition & Health, Active Nutrition, Sokeritehtaantie 20, 02460 Kantvik, Finland
| | - R Burcelin
- 2 INSERM1048, Institut des maladies métaboliques et cardiovasculaires de Rangueil, Rangueil Hospital, 31432 Toulouse, France
| | - S Lahtinen
- 1 DuPont Nutrition & Health, Active Nutrition, Sokeritehtaantie 20, 02460 Kantvik, Finland
| |
Collapse
|
28
|
Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes 2015; 5:437-45. [PMID: 25062610 DOI: 10.3920/bm2014.0014] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Alterations of the gut microbiota and mucosal barrier are linked with metabolic diseases. Our aim was to investigate the potential benefit of the potential probiotic Bifidobacterium animalis ssp. lactis 420 in reducing high-fat diet-induced body weight gain and diabetes in mice. In the obesity model, C57Bl/6J mice were fed a high-fat diet (60 energy %) for 12 weeks, and gavaged daily with B. lactis 420 (109 cfu) or vehicle. In the diabetes model, mice were fed a high-fat, ketogenic diet (72 energy % fat) for 4 weeks, with a 6-week subsequent treatment with B. lactis 420 (108-1010 cfu/day) or vehicle, after which they were analysed for body composition. We also analysed glucose tolerance, plasma lipopolysaccharide and target tissue inflammation using only one of the B. lactis 420 groups (109 cfu/day). Intestinal bacterial translocation and adhesion were analysed in a separate experiment using an Escherichia coli gavage. Body fat mass was increased in both obese (10.7 ± 0.8 g (mean ± standard error of mean) vs. 1.86 ± 0.21 g, P<0.001) and diabetic mice (3.01 ± 0.4 g vs. 1.14 ± 0.15 g, P<0.001) compared to healthy controls. Treatment with B. lactis 420 significantly decreased fat mass in obese (7.83 ± 0.67 g, P=0.007 compared to obese with vehicle) and diabetic mice (1.89 ± 0.16 g, P=0.02 for highest dose). This was reflected as reduced weight gain and improved glucose tolerance. Furthermore, B. lactis 420 decreased plasma lipopolysaccharide levels (P<0.001), liver inflammation (P=0.04), and E. coli adhesion in the distal gut (P<0.05). In conclusion, B. lactis 420 reduces fat mass and glucose intolerance in both obese and diabetic mice. Reduced intestinal mucosal adherence and plasma lipopolysaccharide suggest a mechanism related to reduced translocation of gut microbes.
Collapse
Affiliation(s)
- L K Stenman
- DuPont Nutrition and Health, Active Nutrition, Sokeritehtaantie 20, 02460 Kantvik, Finland
| | - A Waget
- Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil, INSERM1048, Rangueil Hospital, 31432 Toulouse, France
| | - C Garret
- Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil, INSERM1048, Rangueil Hospital, 31432 Toulouse, France
| | - P Klopp
- Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil, INSERM1048, Rangueil Hospital, 31432 Toulouse, France
| | - R Burcelin
- Institut des Maladies Métaboliques et Cardiovasculaires de Rangueil, INSERM1048, Rangueil Hospital, 31432 Toulouse, France
| | - S Lahtinen
- DuPont Nutrition and Health, Active Nutrition, Sokeritehtaantie 20, 02460 Kantvik, Finland
| |
Collapse
|
29
|
Poggi M, Morin SO, Bastelica D, Govers R, Canault M, Bernot D, Georgelin O, Verdier M, Burcelin R, Olive D, Alessi MC, Peiretti F, Nunès JA. CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice. Int J Obes (Lond) 2015; 39:977-85. [PMID: 25771927 DOI: 10.1038/ijo.2015.26] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2014] [Revised: 12/22/2014] [Accepted: 02/08/2015] [Indexed: 01/31/2023]
Abstract
BACKGROUND/OBJECTIVES Lymphocytes have a critical role in visceral adipose tissue (AT) inflammation. The CD28 costimulatory molecule is required for lymphocyte activation and for the development of a functional regulatory T cells (Tregs) compartment; however, its role during obesity is unknown. METHODS During diet-induced obesity, we investigated the effects of selective interference with CD28 signaling using knockout mice (Cd28KO) and a CTLA4-Ig fusion protein inhibiting CD28-B7 interactions. RESULTS Cd28 deficiency decreased pathogenic T cells and Treg content within AT without changing the macrophages number. Cd28KO epididymal but not subcutaneous fat was characterized by enlarged adipocytes, reduced levels of inflammatory cytokines and increased Glut4, adiponectin and lipogenic enzyme mRNA levels. This was associated with reduced inflammation, fat accumulation and enhanced glucose metabolism in liver. Weight gain and fasting glucose tolerance were not affected. CTLA4-Ig injections reduced the number of T cells in epididymal AT (epiAT) but not the inflammatory cytokines levels and failed to improve liver fat accumulation. CONCLUSIONS Deletion of CD28 creates a new pro/anti-inflammatory balance in epiAT and liver and exerts a protective effect against hepatic steatosis.
Collapse
Affiliation(s)
- M Poggi
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - S O Morin
- 1] Inserm, U1068, CRCM, Marseilles, France [2] Institut Paoli-Calmettes, Marseilles, France [3] Aix-Marseille Université, UM 105, Marseilles, France [4] CNRS, UMR7258, CRCM, Marseilles, France
| | - D Bastelica
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - R Govers
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - M Canault
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - D Bernot
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - O Georgelin
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - M Verdier
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - R Burcelin
- 1] Inserm, U1048, Toulouse, France [2] Université Paul Sabatier, IMC, Toulouse Cedex 4, France
| | - D Olive
- 1] Inserm, U1068, CRCM, Marseilles, France [2] Institut Paoli-Calmettes, Marseilles, France [3] Aix-Marseille Université, UM 105, Marseilles, France [4] CNRS, UMR7258, CRCM, Marseilles, France
| | - M-C Alessi
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - F Peiretti
- 1] Inserm, U1062, Marseilles, France [2] Inra, UMR1260, Marseilles, France [3] Aix-Marseille Université, NORT, Marseilles, France
| | - J A Nunès
- 1] Inserm, U1068, CRCM, Marseilles, France [2] Institut Paoli-Calmettes, Marseilles, France [3] Aix-Marseille Université, UM 105, Marseilles, France [4] CNRS, UMR7258, CRCM, Marseilles, France
| |
Collapse
|
30
|
Lobinet E, Reichardt F, Garret C, Cazals L, Waget A, Dejajer S, Labrousse F, Senard JM, Holst JJ, Hanaire H, Burcelin R. Autonomic Diabetic Neuropathy Impairs Glucose and Dipeptidyl Peptidase 4 Inhibitor-Regulated Glucagon Concentration in Type 1 Diabetic Patients. J Endocrinol Metab 2015. [DOI: 10.14740/jem289w] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
31
|
Serino M, Blasco-Baque V, Nicolas S, Burcelin R. Managing the manager: Gut microbes, stem cells and metabolism. Diabetes & Metabolism 2014; 40:186-90. [DOI: 10.1016/j.diabet.2013.12.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 12/09/2013] [Accepted: 12/10/2013] [Indexed: 12/18/2022]
|
32
|
Grasset E, Reichardt F, Garret C, Waget A, Tercé F, Collet X, Burcelin R. O17 La sérotonine intestinale, régulateur de la sécrétion de GLP-1. NUTR CLIN METAB 2013. [DOI: 10.1016/s0985-0562(13)70289-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Moreno-Navarrete JM, Escoté X, Ortega F, Serino M, Campbell M, Michalski MC, Laville M, Xifra G, Luche E, Domingo P, Sabater M, Pardo G, Waget A, Salvador J, Giralt M, Rodriguez-Hermosa JI, Camps M, Kolditz CI, Viguerie N, Galitzky J, Decaunes P, Ricart W, Frühbeck G, Villarroya F, Mingrone G, Langin D, Zorzano A, Vidal H, Vendrell J, Burcelin R, Vidal-Puig A, Fernández-Real JM. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia 2013; 56:2524-37. [PMID: 23963324 DOI: 10.1007/s00125-013-3015-9] [Citation(s) in RCA: 95] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2013] [Accepted: 07/10/2013] [Indexed: 01/12/2023]
Abstract
AIMS/HYPOTHESIS Circulating lipopolysaccharide-binding protein (LBP) is an acute-phase reactant known to be increased in obesity. We hypothesised that LBP is produced by adipose tissue (AT) in association with obesity. METHODS LBP mRNA and LBP protein levels were analysed in AT from three cross-sectional (n = 210, n = 144 and n = 28) and three longitudinal (n = 8, n = 25, n = 20) human cohorts; in AT from genetically manipulated mice; in isolated adipocytes; and in human and murine cell lines. The effects of a high-fat diet and exposure to lipopolysaccharide (LPS) and peroxisome proliferator-activated receptor (PPAR)γ agonist were explored. Functional in vitro and ex vivo experiments were also performed. RESULTS LBP synthesis and release was demonstrated to increase with adipocyte differentiation in human and mouse AT, isolated adipocytes and human and mouse cell lines (Simpson-Golabi-Behmel syndrome [SGBS], human multipotent adipose-derived stem [hMAD] and 3T3-L1 cells). AT LBP expression was robustly associated with inflammatory markers and increased with metabolic deterioration and insulin resistance in two independent cross-sectional human cohorts. AT LBP also increased longitudinally with weight gain and excessive fat accretion in both humans and mice, and decreased with weight loss (in two other independent cohorts), in humans with acquired lipodystrophy, and after ex vivo exposure to PPARγ agonist. Inflammatory agents such as LPS and TNF-α led to increased AT LBP expression in vivo in mice and in vitro, while this effect was prevented in Cd14-knockout mice. Functionally, LBP knockdown using short hairpin (sh)RNA or anti-LBP antibody led to increases in markers of adipogenesis and decreased adipocyte inflammation in human adipocytes. CONCLUSIONS/INTERPRETATION Collectively, these findings suggest that LBP might have an essential role in inflammation- and obesity-associated AT dysfunction.
Collapse
Affiliation(s)
- José María Moreno-Navarrete
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Hospital Universitari 'Dr Josep Trueta', Carretera de França s/n, 17007, Girona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Ortega FJ, Mercader JM, Moreno-Navarrete JM, Sabater M, Pueyo N, Valdés S, Ruiz B, Luche E, Serino M, Naon D, Ricart W, Botas P, Delgado E, Burcelin R, Frühbeck G, Bosch F, Mingrone G, Zorzano A, Fernández-Real JM. Erratum to: Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. J Mol Med (Berl) 2013. [DOI: 10.1007/s00109-013-1014-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Amiot MJ, Romier B, Dao TMA, Fanciullino R, Ciccolini J, Burcelin R, Pechere L, Emond C, Savouret JF, Seree E. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 2013; 95:1233-8. [PMID: 23376875 DOI: 10.1016/j.biochi.2013.01.008] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Accepted: 01/18/2013] [Indexed: 11/15/2022]
Abstract
We have developed an innovative soluble galenic form to overcome the low absorption of trans-Resveratrol (t-Res) as a dry powder. We present here data on pharmacokinetics, bioavailability, and toxicity of t-Res in human volunteers treated with this soluble form, plus additional data on biological effects in rodents. Fifteen healthy volunteers of both sexes received 40 mg of t-Res in two forms, the soluble formulation (caplets) and the original powder (capsules), in a crossover design. Blood samples were collected at 15 min, 30 min, and every hour for 5 h. Plasma concentrations of t-Res and its metabolites were analyzed by liquid chromatography and mass spectrometry. The single dose (40 mg) of the soluble t-Res was well absorbed and elicited biologically efficient blood levels (0.1-6 μM) for several hours, despite metabolization into glucuronide and sulfate conjugates coupled to renal elimination. In contrast, t-Res administered as a dry powder barely elicited efficient blood levels for a short duration. The new formulation led to 8.8-fold higher t-Res levels in plasma versus the powder. t-Res metabolism was not modified and neither intolerance nor toxicity were observed during the study and the following week. The soluble formulation elicited a robust anti-inflammatory effect in various tissues of mice fed a high-fat diet, while dry powder t-Res was almost inactive. Our data suggest that significant improvements in t-Res bioavailability and efficiency can be obtained by this soluble galenic form, also allowing lower doses. The use of t-Res in human therapy is thus greatly facilitated and the toxicity risk is reduced.
Collapse
|
36
|
Ortega FJ, Mercader JM, Moreno-Navarrete JM, Sabater M, Pueyo N, Valdés S, Ruiz B, Luche E, Serino M, Naon D, Ricart W, Botas P, Delgado E, Burcelin R, Frühbeck G, Bosch F, Mingrone G, Zorzano A, Fernández-Real JM. Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. J Mol Med (Berl) 2012. [PMID: 23207880 DOI: 10.1007/s00109-012-0979-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Calgranulin B (S100A9) was recognized as a candidate type 2 diabetes (T2D) gene in the genomic profiling of muscle from a rodent model of T2D and identifying the human orthologs of genes localized in T2D susceptibility regions. Circulating and S100A9 expressions in muscle and adipose tissue, isolated fat cells, and mouse models were evaluated. A common 5'-upstream single-nucleotide polymorphism (SNP; rs3014866) for S100A9 was analyzed, as well as the effects of weight loss and treatments in vitro with recombinant S100A9. S100a9 expression was increased in muscle of diabetic mice (1.6-fold, p = 0.002), and in muscle from subjects with impaired glucose tolerance (∼4-fold, p = 0.028; n = 34). The rs3014866 SNP was associated with circulating S100A9 and the risk of T2D, having TT carriers at 28 % (p = 0.03) lower risk (n = 1,450). Indeed, increased circulating S100A9 (∼4-fold, p = 0.03; n = 206) and subcutaneous (2-fold, p = 0.01) and omental (1.4-fold, p = 0.04) S100A9 gene expressions (n = 83) in TT carriers run in parallel to decreased fasting glucose and glycated hemoglobin. Accordingly, metformin led to increased S100A9 mRNA in ex vivo-treated adipose tissue explants (n = 5/treatment). Otherwise, obese subjects showed a compensatory increase in circulating and S100A9 expressions in adipose (n = 126), as further demonstrated by decreased levels after diet- (-34 %, p = 0.002; n = 20) and surgery-induced (-58 %, p = 0.02; n = 8) weight loss. Lipopolysaccharide led to increased S100A9 in adipose from mice (n = 5/treatment) while recombinant S100A9 downregulated inflammation in adipocytes (n = 3/treatment). Current findings support the strategy of testing differentially expressed genes in mice and human orthologs associated with T2D. The increased S100A9 reported for obesity and insulin resistance may be envisioned as a compensatory mechanism for inflammation.
Collapse
Affiliation(s)
- Francisco J Ortega
- Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomédica de Girona (IdIBGi), CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Blasco-Baque V, Serino M, Burcelin R. [Metabolic therapy at the edge between human hosts and gut microbes]. Ann Pharm Fr 2012; 71:34-41. [PMID: 23348854 DOI: 10.1016/j.pharma.2012.08.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 08/28/2012] [Accepted: 08/29/2012] [Indexed: 12/26/2022]
Abstract
Personalized medicine is becoming day-after-day more urgent taking into account the great diversity characterizing patients affected by a given pathology, especially metabolic diseases. In fact, antidiabetic/obesity treatments have shown a reduced or no effect at all in some patients, representing a major challenge physicians have to face worldwide. Therefore, efforts have to be put to identify individual factors affecting our susceptibility towards a given medication. In that regard, gut microbiota may stand for the missing piece of the metabolic puzzle regulating host response, since its role in the induction of metabolic diseases has now been achieved. In fact, we firstly provided a bacterial explanation for the low-grade chronic inflammation featuring metabolic diseases, by showing the lipopolysaccharide as a trigger and risk factor of such pathologies. However, despite similar lineages of microbes characterize the gut of people, important differences still remain, which may be responsible for opposite effect of treatments such as pre- or probiotics, whose efficacy seems to be governed by the own gut microbiota of subjects. We have recently shown that gut microbiota is associated to the inclination to resist or not high-fat diet-induced type 2 diabetes in mice. In addition, the direct targeting of gut microbes by dietary fibers reversed the observed metabolic phenotype. These results, together with the literature, strongly suggest gut microbiota as a new target for the development of personalized metabolic therapy.
Collapse
Affiliation(s)
- V Blasco-Baque
- Institut national de la santé et de la recherche médicale (Inserm), UMR 1048, Toulouse, France
| | | | | |
Collapse
|
38
|
Briand F, Thieblemont Q, Burcelin R, Sulpice T. Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes Obes Metab 2012; 14:662-5. [PMID: 22268579 DOI: 10.1111/j.1463-1326.2012.01568.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Dipeptidyl peptidase-4 inhibitors (DPP-4i) improve glycaemic control in type 2 diabetes, but their benefits on reverse cholesterol transport (RCT) remain unknown. We evaluated the effects of DPP-4i sitagliptin 500 mg/kg/day on RCT in obese insulin-resistant CETP-apoB100 transgenic mice. Metformin 300 mg/kg/day orally was used as a reference compound. Both metformin and sitagliptin showed the expected effects on glucose parameters. Although no significant effect was observed on total cholesterol and high-density lipoprotein (HDL) cholesterol levels, sitagliptin, but not metformin, increased faecal cholesterol mass excretion by 132% (p < 0.001 vs. vehicle), suggesting a potent effect on cholesterol metabolism. Mice were then injected i.p. with (3) H-cholesterol labelled macrophages to measure RCT over 48 h. Compared with vehicle, sitagliptin significantly increased macrophage-derived (3) H-cholesterol faecal excretion by 39%. Administration of (14) C-cholesterol labelled olive oil orally showed a significant reduction of (14) C-tracer plasma appearance over time with sitagliptin, indicating that this drug promotes RCT through reduced intestinal cholesterol absorption.
Collapse
Affiliation(s)
- F Briand
- Physiogenex SAS, Prologue Biotech, Rue Pierre et Marie Curie, Rue Pierre et Marie Curie, Labège-Innopole, France.
| | | | | | | |
Collapse
|
39
|
Holmes E, Kinross J, Gibson GR, Burcelin R, Jia W, Pettersson S, Nicholson JK. Therapeutic Modulation of Microbiota-Host Metabolic Interactions. Sci Transl Med 2012; 4:137rv6. [DOI: 10.1126/scitranslmed.3004244] [Citation(s) in RCA: 181] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
40
|
Abstract
The composition and activity of the gut microbiota codevelop with the host from birth and is subject to a complex interplay that depends on the host genome, nutrition, and life-style. The gut microbiota is involved in the regulation of multiple host metabolic pathways, giving rise to interactive host-microbiota metabolic, signaling, and immune-inflammatory axes that physiologically connect the gut, liver, muscle, and brain. A deeper understanding of these axes is a prerequisite for optimizing therapeutic strategies to manipulate the gut microbiota to combat disease and improve health.
Collapse
Affiliation(s)
- Jeremy K Nicholson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
| | | | | | | | | | | | | |
Collapse
|
41
|
Blasco-Baque V, Kémoun P, Loubieres P, Roumieux M, Heymes C, Serino M, Sixou M, Burcelin R. [Impact of periodontal disease on arterial pressure in diabetic mice]. Ann Cardiol Angeiol (Paris) 2012; 61:173-177. [PMID: 22621847 DOI: 10.1016/j.ancard.2012.04.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Accepted: 04/15/2012] [Indexed: 06/01/2023]
Abstract
Diabetes-driven cardiovascular diseases represent a high challenge for developed countries. Periodontal disease is strictly linked to the aforementioned diseases, due to its Gram negative-driven inflammation. Thus, we investigated the effects of periodontal disease on arterial pressure during the development of diabetes in mice. To this aim, C57BL/6 female mice were colonized with pathogens of periodontal tissue (Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum) for 1month, whereas another group of mice did not undergo the colonization. Subsequently, all mice were fed a high-fat carbohydrate-free diet for 3months. Then, arterial pressure was measured in vivo and a tomodensitometric analysis of mandibles was realized as well. Our results show increased mandibular bone-loss induced by colonization with periopathogens. In addition, periodontal infection augmented glucose-intolerance and systolic and diastolic arterial pressure, parameters already known to be affected by a fat-diet. In conclusion, we show here that periodontal disease amplifies metabolic troubles and deregulates arterial pressure, emerging as a new axis of metabolic investigation.
Collapse
Affiliation(s)
- V Blasco-Baque
- Parodontites et maladies générales LU 51, faculté de chirurgie dentaire, 3, chemin des Maraîchers, 31062 Toulouse cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Maris M, Overbergh L, Gysemans C, Waget A, Cardozo AK, Verdrengh E, Cunha JPM, Gotoh T, Cnop M, Eizirik DL, Burcelin R, Mathieu C. Deletion of C/EBP homologous protein (Chop) in C57Bl/6 mice dissociates obesity from insulin resistance. Diabetologia 2012; 55:1167-78. [PMID: 22237685 DOI: 10.1007/s00125-011-2427-7] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2011] [Accepted: 11/29/2011] [Indexed: 01/23/2023]
Abstract
AIMS/HYPOTHESIS Endoplasmic reticulum (ER) stress has been implicated in the development of type 2 diabetes, via effects on obesity, insulin resistance and pancreatic beta cell health. C/EBP homologous protein (CHOP) is induced by ER stress and has a central role in apoptotic execution pathways triggered by ER stress. The aim of this study was to characterise the role of CHOP in obesity and insulin resistance. METHODS Metabolic studies were performed in Chop ( -/- ) and wild-type C57Bl/6 mice, and included euglycaemic-hyperinsulinaemic clamps and indirect calorimetry. The inflammatory state of liver and adipose tissue was determined by quantitative RT-PCR, immunohistology and macrophage cultures. Viability and absence of ER stress in islets of Langerhans was determined by electron microscopy, islet culture and quantitative RT-PCR. RESULTS Systemic deletion of Chop induced abdominal obesity and hepatic steatosis. Despite marked obesity, Chop ( -/- ) mice had preserved normal glucose tolerance and insulin sensitivity. This discrepancy was accompanied by lower levels of pro-inflammatory cytokines and less infiltration of immune cells into fat and liver. CONCLUSIONS/INTERPRETATION These observations suggest that insulin resistance is not induced by fat accumulation per se, but rather by the inflammation induced by ectopic fat. CHOP may play a key role in the crosstalk between excessive fat deposition and induction of inflammation-mediated insulin resistance.
Collapse
Affiliation(s)
- M Maris
- Catholic University of Leuven, Leuven, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, Waget A, Klopp P, Iacovoni J, Klopp C, Mariette J, Bouchez O, Lluch J, Ouarné F, Monsan P, Valet P, Roques C, Amar J, Bouloumié A, Théodorou V, Burcelin R. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2012; 61:543-53. [PMID: 22110050 PMCID: PMC3292714 DOI: 10.1136/gutjnl-2011-301012] [Citation(s) in RCA: 440] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE The gut microbiota, which is considered a causal factor in metabolic diseases as shown best in animals, is under the dual influence of the host genome and nutritional environment. This study investigated whether the gut microbiota per se, aside from changes in genetic background and diet, could sign different metabolic phenotypes in mice. METHODS The unique animal model of metabolic adaptation was used, whereby C57Bl/6 male mice fed a high-fat carbohydrate-free diet (HFD) became either diabetic (HFD diabetic, HFD-D) or resisted diabetes (HFD diabetes-resistant, HFD-DR). Pyrosequencing of the gut microbiota was carried out to profile the gut microbial community of different metabolic phenotypes. Inflammation, gut permeability, features of white adipose tissue, liver and skeletal muscle were studied. Furthermore, to modify the gut microbiota directly, an additional group of mice was given a gluco-oligosaccharide (GOS)-supplemented HFD (HFD+GOS). RESULTS Despite the mice having the same genetic background and nutritional status, a gut microbial profile specific to each metabolic phenotype was identified. The HFD-D gut microbial profile was associated with increased gut permeability linked to increased endotoxaemia and to a dramatic increase in cell number in the stroma vascular fraction from visceral white adipose tissue. Most of the physiological characteristics of the HFD-fed mice were modulated when gut microbiota was intentionally modified by GOS dietary fibres. CONCLUSIONS The gut microbiota is a signature of the metabolic phenotypes independent of differences in host genetic background and diet.
Collapse
Affiliation(s)
- Matteo Serino
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Elodie Luche
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Sandra Gres
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Audrey Baylac
- Université de Toulouse III, UPS, LU49, Adhésion Bactérienne et Formation de Biofilms, Toulouse Cedex 9, France
| | - Mathieu Bergé
- Université de Toulouse III, UPS, LU49, Adhésion Bactérienne et Formation de Biofilms, Toulouse Cedex 9, France
| | - Claire Cenac
- Neuro-Gastroenterology and Nutrition Unit, UMR INRA/EI-Purpan, Toulouse Cedex 3, France
| | - Aurelie Waget
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Pascale Klopp
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Jason Iacovoni
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Christophe Klopp
- Plateforme Bio-informatique Toulouse Genopole®, UBIA INRA, Castanet-Tolosan Cedex, France
| | - Jerome Mariette
- Plateforme Bio-informatique Toulouse Genopole®, UBIA INRA, Castanet-Tolosan Cedex, France
| | - Olivier Bouchez
- GENOTOUL Platform, INRA Chemin de Borde-Rouge, Auzeville, France
| | - Jerome Lluch
- GENOTOUL Platform, INRA Chemin de Borde-Rouge, Auzeville, France
| | - Francoise Ouarné
- Université de Toulouse III, INSA, UPS, INP, LISBP, Toulouse, France
| | - Pierre Monsan
- Université de Toulouse III, INSA, UPS, INP, LISBP, Toulouse, France,CNRS, UMR5504, Toulouse, France,INRA, UMR792 Ingénierie des Systèmes Biologiques et des Procédés, Toulouse, France,Institut Universitaire de France, Paris, France
| | - Philippe Valet
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Christine Roques
- Université de Toulouse III, UPS, LU49, Adhésion Bactérienne et Formation de Biofilms, Toulouse Cedex 9, France
| | - Jacques Amar
- Rangueil Hospital, Department of Therapeutics, Toulouse, France
| | - Anne Bouloumié
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| | - Vassilia Théodorou
- Neuro-Gastroenterology and Nutrition Unit, UMR INRA/EI-Purpan, Toulouse Cedex 3, France
| | - Remy Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France,Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut de Maladies Métaboliques et Cardiovasculaires (IMC), Toulouse Cedex 4, France
| |
Collapse
|
44
|
Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, Salvador J, Ricart W, Frühbeck G, Burcelin R, Fernández-Real JM. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2011; 36:1442-9. [PMID: 22184060 DOI: 10.1038/ijo.2011.256] [Citation(s) in RCA: 152] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Lipopolysaccharide-binding protein (LBP) is a 65-kDa acute-phase protein present in blood at high concentrations, known to be derived from the liver. We aimed to gain insights into the association of circulating LBP with insulin resistance in humans and mice. METHODS, DESIGN AND MEASUREMENTS: We studied the cross-sectional (n=222) and weight loss-induced (n=34) associations of LBP (enzyme-linked immunosorbent assay) with inflammatory and metabolic parameters (including minimal model-measured insulin sensitivity), and the effects of high-fat diet (HFD), metformin and genetic insulin sensitization (glucagon-like peptide 1 receptor knockout model) in mice. RESULTS Circulating LBP concentration was significantly increased in subjects with type 2 diabetes and dramatically increased in subjects with morbid obesity. LBP was significantly associated with insulin sensitivity and different inflammatory markers and decreased after weight loss (22.2 ± 5.8 vs 16.2 ± 9.3 μg ml(-1), P<0.0001) in association with changes in body mass index and insulin sensitivity. Circulating LBP concentration was increased in HFD mice, whereas decreased in glucagon-like peptide 1 receptor knockout mice (significantly more insulin sensitive than wild-type mice) and after metformin administration. CONCLUSION LBP is an inflammatory marker associated with obesity-related insulin resistance.
Collapse
Affiliation(s)
- J M Moreno-Navarrete
- Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, Lepage P, Klopp C, Mariette J, Bouchez O, Perez L, Courtney M, Marre M, Klopp P, Lantieri O, Doré J, Charles MA, Balkau B, Burcelin R. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia 2011; 54:3055-61. [PMID: 21976140 DOI: 10.1007/s00125-011-2329-8] [Citation(s) in RCA: 205] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Accepted: 09/09/2011] [Indexed: 10/17/2022]
Abstract
AIMS/HYPOTHESIS Evidence suggests that bacterial components in blood could play an early role in events leading to diabetes. To test this hypothesis, we studied the capacity of a broadly specific bacterial marker (16S rDNA) to predict the onset of diabetes and obesity in a general population. METHODS Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) is a longitudinal study with the primary aim of describing the history of the metabolic syndrome. The 16S rDNA concentration was measured in blood at baseline and its relationship with incident diabetes and obesity over 9 years of follow-up was assessed. In addition, in a nested case-control study in which participants later developed diabetes, bacterial phylotypes present in blood were identified by pyrosequencing of the overall 16S rDNA gene content. RESULTS We analysed 3,280 participants without diabetes or obesity at baseline. The 16S rDNA concentration was higher in those destined to have diabetes. No difference was observed regarding obesity. However, the 16S rDNA concentration was higher in those who had abdominal adiposity at the end of follow-up. The adjusted OR (95% CIs) for incident diabetes and for abdominal adiposity were 1.35 (1.11, 1.60), p = 0.002 and 1.18 (1.03, 1.34), p = 0.01, respectively. Moreover, pyrosequencing analyses showed that participants destined to have diabetes and the controls shared a core blood microbiota, mostly composed of the Proteobacteria phylum (85-90%). CONCLUSIONS/INTERPRETATION 16S rDNA was shown to be an independent marker of the risk of diabetes. These findings are evidence for the concept that tissue bacteria are involved in the onset of diabetes in humans.
Collapse
Affiliation(s)
- J Amar
- Inserm U1027, University Paul Sabatier, CHU, Hôpital Rangueil, Avenue Jean Pouhles, Toulouse, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Blasco-Baque V, Kemoun P, Loubieres P, Arnal JF, Gourdy P, Serino M, Burcelin R, Sixou M. Impact of type 2 diabetes on the development of periodontal disease in the mouse. Bull Group Int Rech Sci Stomatol Odontol 2011; 50:11-12. [PMID: 22750698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Accepted: 11/22/2011] [Indexed: 06/01/2023]
Affiliation(s)
- V Blasco-Baque
- Parodontites et maladies générales L.U. 46 Faculté de chirurgie dentaire, 3 chemin des Maraîchers, Toulouse Cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Fernández-Real JM, Pérez del Pulgar S, Luche E, Moreno-Navarrete JM, Waget A, Serino M, Sorianello E, Sánchez-Pla A, Pontaque FC, Vendrell J, Chacón MR, Ricart W, Burcelin R, Zorzano A. CD14 modulates inflammation-driven insulin resistance. Diabetes 2011; 60:2179-86. [PMID: 21700881 PMCID: PMC3142089 DOI: 10.2337/db10-1210] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
OBJECTIVE The study objective was to evaluate the possible role of the macrophage molecule CD14 in insulin resistance. RESEARCH DESIGN AND METHODS The effects of recombinant human soluble CD14 (rh-sCD14) on insulin sensitivity (clamp procedure) and adipose tissue gene expression were evaluated in wild-type (WT) mice, high fat-fed mice, ob/ob mice, and CD14 knockout (KO) mice. We also studied WT mice grafted with bone marrow stem cells from WT donor mice and CD14 KO mice. Finally, CD14 was evaluated in human adipose tissue and during differentiation of human preadipocytes. RESULTS rh-sCD14 led to increased insulin action in WT mice, high-fat-fed mice, and ob/ob mice, but not in CD14 KO mice, in parallel to a marked change in the expression of 3,479 genes in adipose tissue. The changes in gene families related to lipid metabolism were most remarkable. WT mice grafted with bone marrow stem cells from WT donor mice became insulin resistant after a high-fat diet. Conversely, WT mice grafted with cells from CD14 KO mice resisted the occurrence of insulin resistance in parallel to decreased mesenteric adipose tissue inflammatory gene expression. Glucose intolerance did not worsen in CD14 KO mice grafted with bone marrow stem cells from high fat-fed WT mice when compared with recipient KO mice grafted with cells from CD14 KO donor mice. CD14 gene expression was increased in whole adipose tissue and adipocytes from obese humans and further increased after tumor necrosis factor-α. CONCLUSIONS CD14 modulates adipose tissue inflammatory activity and insulin resistance.
Collapse
Affiliation(s)
- José Manuel Fernández-Real
- Section of Diabetes, Endocrinology and Nutrition, University Hospital of Girona, Biomedical Research Institute Dr Josep Trueta and CIBERobn Fisiopatología de la Obesidad y Nutrición, Girona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Amar J, Serino M, Lange C, Chabot C, Bouchez O, Mariette J, Perez L, Courntey M, Marre M, Klopp P, Lantieri O, Dore J, Charles MA, Balkau B, Burcelin R. PREDICTIVE VALUE OF BLOOD BACTERIAL DNA ON THE ONSET OF TYPE 2 DIABETES FROM GENERAL POPULATION. J Hypertens 2011. [DOI: 10.1097/00004872-201106001-00288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Abstract
Glucose homeostasis corresponds to the overall physiological, cellular, and molecular mechanisms which tightly maintain the glycaemia between ∼4.5 and ∼6 mM. The resulting blood glucose concentration is the consequence of a balance between the mechanisms that ensure the entry and the output of glucose in the blood. A dynamic balance needs hence to be perfectly achieved in order to maintain a physiological glycaemic concentration. Specialized cells from the intestine continuously detect changes in glucose concentration and send signals to peripheral tissues and the brain through the vagus nerve. The molecular mechanisms involved in glucose detection have not been perfectly defined but could resemble those from the insulin-secreting beta cells. The brain then integrates the enteric and circulating endocrine signals to generate a new signal towards peripheral tissues such as the pancreas, liver, muscles, and blood vessels. This metabolic reflex is called anticipatory since it allows the peripheral tissues to prepare for the adequate handling of nutrients. Diabetes is associated with an impaired anticipatory reflex, which hampers the proper detection of nutrients and leads to hyperglycaemic episodes. Recently, GLP-1-based therapies have demonstrated the improvement of glucose detection and their efficacy on glycaemic control. Although not yet fully demonstrated, GLP-1-based therapies regulate glucose sensors, which leads to the glycaemic improvement. Certainly other molecular targets could be identified to further generate new therapeutic strategies.
Collapse
Affiliation(s)
- R Burcelin
- Institut National de la Santé et de la Recherche Médicale (INSERM), U858, Toulouse, France.
| |
Collapse
|
50
|
Abstract
In the past few years, the development of pharmaceutical agents that enhance the physiological effects of glucagon-like peptide-1 (GLP-1), either through GLP-1 receptor agonism (GLP-1 agonists) or by inhibiting GLP-1 degradation (dipeptidylpeptidase-4 inhibitors) has broadened the range of treatment options for individuals with type 2 diabetes. It has been recognized for some time that GLP-1 also has extra-pancreatic effects, notably targeting the brain, where it regulates appetite and satiety, as well as peripheral functions highly controlled by the autonomic nervous system, such as gastric emptying. Furthermore, data are beginning to emerge that indicate a potential role for GLP-1 in neuroprotection. The increased risk of Alzheimer's disease, Parkinson's disease and stroke in people with type 2 diabetes suggests that shared mechanisms/pathways of cell death, possibly related to insulin dysregulation, may underlie all of these disorders. Although the disease anatomy varies with each disorder, a wide range of genetic and environmental triggers result in activation of similar biochemical pathways in all of them, suggesting a complex network of biochemical events that feed in to a final common path towards cellular dysfunction and death. This article summarizes the evidence for neuronal activity of GLP-1 and examines the limited data that currently exist on the therapeutic potential of GLP-1 in specific neurological and neurodegenerative conditions, namely Alzheimer's disease, Parkinson's disease, Huntingdon's disease, stroke and peripheral sensory neuropathy.
Collapse
Affiliation(s)
- Jens Juul Holst
- Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.
| | | | | |
Collapse
|